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ABSTRACT 
 
Cardiomyocytes derived from embryonic stem cells (ESCs) offer a great alternative to 
generate a large number of cells with potential application in biomedical research and drug or 
toxicology screening. Although the differentiation efficiency can be improved by the genetic 
manipulation of ESCs to over-express cardiac-specific transcription factors, current protocols 
for differentiation are time consuming, have low yield, and lack of reproducibility. Protein 
transduction has been demonstrated as an alternative approach for increasing the efficiency of 
ESCs differentiation toward cardiomyocytes. 
The objective of this work was to produce a recombinant chimeric protein with the 
intrinsic ability to transduce into cells. In this work, we successfully produced and purified a 
novel recombinant protein from bacteria, which is capable of overcome the cellular membrane 
barrier. This protein is composed by two domains: the human protein CITED2 fused at its N-
terminal domain to a Protein Transduction Domain (PTD), rich in arginines, which confers 
biologically active proteins the capability to translocate across the membrane and deliver 
them inside the cell.  
We showed that CITED2 recombinant protein, added to the culture medium of the 
cells, was successfully internalized, localized in the nucleus and functional. In mouse 
embryonic stem cells (mESC), the knockout of Cited2 gene impairs these cells to differentiate 
into cardiomyocytes. We showed that the supplementation, on the second day of 
differentiation, of CITED2 recombinant protein to the culture medium of Cited2 depleted 
cells, rescued the cardiogenic defects of these cells. On the other hand, the supplementation at 
the onset of differentiation, while the cells are still in a pluripotent state, suggested a delay in 
the overall differentiation process.  
Although further studies are still required, the direct application of the developed 
recombinant protein suggests a capability to replace the endogenous protein effects, further 
suggesting that CITED2 protein has a relevant role in cardiogenesis and pluripotency. 
 
Keywords: Cardiac differentiation, Cited2, Mouse Embryonic Stem Cells, Protein 
Transduction Domain, Recombinant protein. 
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RESUMO 
 
A utilização de cardiomiócitos derivados de células estaminais embrionárias (ESC) 
permite-nos acesso a um grande número de células para investigação biomédica e uso de 
fármacos ou ensaios toxicológicos. Apesar de ser possível aumentar a eficiência de 
diferenciação através de manipulação genética sobre expressando fatores cardíacos 
específicos, os protocolos atuais são bastante morosos, têm baixo rendimento e são 
dificilmente reprodutíveis. A transdução proteica é um método alternativo para aumentar a 
eficácia de diferenciação de células estaminais embrionárias em cardiomiócitos. 
 
O objetivo consistiu na construção de uma proteína quimérica com a capacidade 
intrínseca de transdução celular. Produzimos e purificámos esta proteína recombinante, com a 
capacidade de atravessar a membrana celular, sendo composta por dois domínios: a proteína 
humana CITED2, ligada através do domínio terminal-N a um Domínio de Transdução 
Proteica (PTD), rico em argininas, que confere a capacidade de transduzir proteínas 
biologicamente ativas e entregá-las no interior da célula.  
Com este trabalho, conseguimos demonstrar que esta proteína recombinante CITED2, 
quando adicionada ao meio de cultura celular, atravessa a membrana celular, alcança o 
núcleo, e é funcional.  
Em células embrionárias de ratinho (mESC), o knockout do gene Cited2 leva à 
diferenciação destas células em cardiomiócitos. A suplementação com a proteína 
recombinante CITED2, no segundo dia de diferenciação, no meio de cultura em que as células 
tinham sofrido a depleção de Cited2, tem a capacidade de compensar os defeitos na 
diferenciação cardíaca. Por outro lado, se o meio de cultura for suplementado na fase inicial 
de diferenciação (dia 0), enquanto as células ainda se encontram num estado de pluripotência, 
sugere um atraso no processo de diferenciação geral.  
Apesar de serem necessários estudos mais aprofundados, a aplicação direta da proteína 
desenvolvida parece ter a capacidade de substituição dos efeitos causados pela proteína 
endógena, sugerindo assim que a proteína CITED2 desempenha um papel importante tanto 
em cardiogénese como em pluripotência. 
Resumo 
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ratinho, Domínio de Transdução Proteica, Proteína recombinante. 
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RESUMO ALARGADO 
 
As doenças cardiovasculares são a principal causa de morte nos países desenvolvidos, 
constituindo um problema de saúde pública que urge minorar. No entanto, o coração tem uma 
capacidade limitada de regeneração e quando uma lesão ocorre, este não consegue substituir o 
tecido cardíaco danificado por novo músculo cardíaco, pois os cardiomiócitos (células 
altamente diferenciadas do coração com propriedades contráteis) morrem quer por apoptose 
ou necrose do tecido. Assim, essas células são substituídas por fibroblastos que contribuem 
para a formação de tecido cicatricial, tornando o coração mais frágil, com as suas 
propriedades contráteis comprometidas. 
Um dos principais objetivos da investigação biomédica tem sido o desenvolvimento de 
métodos para a geração de cardiomiócitos de novo, tanto in vitro como in vivo, tal como 
novas ferramentas terapêuticas e métodos para regenerar o músculo cardíaco. Tendo em conta 
a informação anterior, um modo de tentar investigar os mecanismos moleculares que 
contribuem para o desenvolvimento de doenças do miocárdio, é essencialmente gerar 
cardiomiócitos funcionais, uma vez que a sua utilização na descoberta de medicamentos e 
estudos de toxicidade seria altamente benéfico, pois iria permitir testar novas moléculas 
farmacológicas para o tratamento deste tipo de doença. A solução ideal seria obter novas 
células, com propriedades contráteis de modo a reparar o tecido danificado.  
As células estaminais são consideradas uma das mais promissoras fontes de células 
para regeneração, sendo que vários tecidos humanos já foram propostos como uma fonte de 
células estaminais com potencial cardiogénico (e portanto, capaz de gerar novos 
cardiomiócitos). O transplante autólogo de células estaminais dos próprios pacientes constitui 
uma das melhores hipóteses propostas para a reparação eficiente de corações fragilizados por 
doenças cardíacas, principalmente devido ao potencial de populações de células estaminais 
(como as células progenitoras cardíacas (CPCs)) que podem contribuir para promover a 
regeneração cardíaca.  
Relativamente à diferenciação celular em cardiomiócitos, para gerar células seguras 
para aplicações terapêuticas é essencial evitar integração viral, e portanto é fundamental 
reduzir e evitar a manipulação genética, tornando a produção e aplicação de proteínas 
recombinantes uma alternativa mais viável para a expressão do gene em estudo. 
Resumo Alargado 
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Cited2, um gene que codifica uma proteína nuclear, liga-se diretamente e com elevada 
afinidade, à primeira região enriquecida com cisteína e histidinas (CH1) do p300 e CBP, 
estando presente em todos vertebrados. Vários estudos demonstraram que as 
variações/mutações no gene Cited2 está relacionada com defeitos cardíacos congénitos. 
Foi observado que Cited2 é essencial na manutenção da pluripotência uma vez que 
regula diretamente a expressão de fatores de transcrição tal como Oct4, Sox2, Nanog, Klf4 e 
Tbx3, que fazem parte da rede nuclear dos genes responsáveis pelo estado de pluripotência 
nas ESC. Uma variação dos níveis de expressão destes reguladores de pluripotência dos níveis 
de expressão ótimos, levam à diferenciação das ESC. Vários estudos suportam esta hipótese, 
uma vez que a sobrexpressão de CITED2 em mESC suporta a autorrenovação destas células, 
mesmo na ausência de leukemia inhibitory factor (LIF). Pelo contrário, a ausência de CITED2 
durante a diferenciação de mESC leva a um atraso em genes de autorrenovação, ativando vias 
de diferenciação hematopoiéticas, neuronais e cardíacas.  
A entrega intracelular de macromoléculas biológicas (como por exemplo fármacos) 
constituem um campo importante da medicina, uma vez que muitas macromoléculas 
biológicas, como as proteínas, péptidos, e ácidos nucleicos têm demonstrado ser úteis para o 
tratamento de vários problemas de saúde. No entanto, a entrega de macromoléculas nos seus 
locais-alvo não é fácil, principalmente devido à estrutura da membrana celular eucariótica. 
Um dos sistemas que podem ser utilizados para superar este problema, é a aplicação de 
domínios de transdução proteicos (PTDs), que são capazes de transportar a moléculas 
associadas através da membrana e desta forma permitir a entrada das proteínas 
biologicamente ativas no interior da célula. 
Assim sendo, o objetivo desta tese foi a produção de uma proteína recombinante com 
a capacidade de transdução celular. Neste trabalho, clonámos o gene Cited2 num plasmídeo, 
de modo a produzir uma nova proteína recombinante. Esta proteína consiste na fusão de 
CITED2 com um péptido rico em argininas, denominado PTD, através do domínio terminal-
N. Este PTD tem a capacidade de atravessar a membrana celular e desta forma, seria capaz de 
transportar a proteína CITED2 para o interior da célula.  
Assim, este projeto de investigação pode ser dividido em três etapas gerais: 
• Clonagem molecular dos fragmentos de DNA no plasmídeo pGEX-6P-1; 
• Produção e purificação das proteínas recombinantes; 
Resumo Alargado 
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• Realização de ensaios celulares para análise da entrada e efeitos na pluripotência e 
diferenciação cardíaca em células estaminais embrionárias de ratinho. 
 
Tendo em conta o objetivo proposto, começámos por clonar os fragmentos de DNA 
desejados num plasmídeo que permitiria a posterior produção destas proteínas. Após a 
produção das proteínas recombinantes TAT-CITED2 e 8R-CITED2, estas foram purificadas 
através de FPLC: TAT-CITED2 e 8R-CITED2. No entanto, a validação funcional a nível 
celular foi testada apenas com a proteína 8R-CITED2 por falta de tempo.  
Quando suplementada no meio de cultura, a proteína recombinante 8R-CITED2 
demonstrou ter sido internalizada nas células. A atividade da mesma foi comprovada através 
de um ensaio de BiFC, onde se demonstrou a competitividade contra a proteína CITED2 
endógena pelo domínio p300. Por último, em ensaios de diferenciação celular, a proteína 
recombinante apresentou um padrão semelhante à proteína endógena quando esta última é 
suprimida. Ao estudar o papel desta proteína recombinante, podemos concluir que esta tem a 
capacidade de restauração dos defeitos causado pelo knockout de Cited2 endógeno em mESC 
quando aplicada ao meio de cultura no segundo dia de diferenciação, e parece ter alguma 
influência no atraso da diferenciação cardíaca quando o meio é suplementado no dia 0. 
Usando esta abordagem, esta proteína pode ser utilizada para expandir células 
estaminais embrionárias de ratinho num ambiente controlado e auxiliar no controlo da 
diferenciação destas células. Este método oferece melhores alternativas do que os métodos 
utilizados anteriormente, visto que envolvem transfeções que geralmente resultam em 
sistemas artificiais e níveis subótimos de CITED2. No entanto, pesquisas e ensaios adicionais 
são necessários para aumentar a eficiência e segurança desta proteína recombinante. 
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I. INTRODUCTION 
 
I.1. CARDIOVASCULAR DISEASE 
Heart disease is the leading cause of mortality worldwide, resulting in 17.3 million 
deaths (31.5%) in 2013 up from 12.3 million (25.8%) in 1990, with insufficient therapeutic 
options and poor prognosis.1,2 Cardiovascular disease affects older adults, amongst which 
coronary artery disease and stroke account for 80% of deaths in males and 75% of deaths in 
females with cardiovascular disease.3 
Despite significant advances in therapeutic modalities and prevention strategies, the 
high mortality rates associated with heart disease is fearsome. This has driven research into 
new therapeutic strategies including cardiac regenerative therapy as a new approach for 
severe cardiac diseases resistant to the conventional treatments.1 
To investigate the molecular mechanisms leading to myocardial diseases in humans, it 
is essential to generate functional cardiomyocytes. Their use in drug discovery and toxicology 
studies would be highly beneficial, allowing that new pharmacological molecules for the 
treatment of cardiac disorders to be validated pre-clinically on cells of human origin.4  
Recent studies from several laboratories have demonstrated that cardiomyocyte 
turnover occurs throughout life in mammals. However, most of the reports find a remarkably 
low annual post-natal cardiomyocyte renewal rate of approximately 1%, which increases 
modestly after injury but declines with age.2 The regenerative potential of the adult 
mammalian heart is very limited and when a lesion occurs it cannot replace the damaged 
cardiac tissue with new function muscle, since the cardiomyocytes die either by apoptosis or 
necrosis of the tissue. Then these cells are replaced by fibroblasts for scar tissue formation, 
turning the heart fragile, without good contractile properties.2,5,6  
An optimal solution is to obtain new cells, with contractile properties to replace the 
injured tissue. However the access to the human heart tissue is very limited, and although 
human cardiomyocytes could be isolated from heart through biopsies, the procedure is 
complicated, invasive,  unpractical to obtain viable cell preparations in large quantities (since 
they lack of proliferation capacity), and the majority of the cells acquired do not beat 
spontaneously.6,7 
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To overcome this problem, biomedical research fields have been developing methods 
for the generation of de novo cardiomyocytes, both in vitro and in vivo, together with novel 
therapeutic tools and approaches to regenerate cardiac muscle for diseased hearts.2,5,6 
The development of new approaches has resulted in the isolation of cardiomyocytes 
from various new-born animals or the production of genetically engineered cell lines. 
Nevertheless, these models have significant limitations since they present basic physiological 
differences in comparison to human cardiomyocytes as well as high costs and ethical 
questions.8,9 
Regarding cardiac cell-based treatments, stem cells are a promising cell source, which 
are being prioritized by scientists for basic research and clinical trials.10,11 Several different 
human tissues have already been proposed as a source of stem cells with cardiogenic potential 
(therefore capable to generate new cardiomyocytes) (e.g., fetal cardiomyocytes, adult cardiac 
progenitor cells, skeletal myoblasts, bone marrow-derived stem cells, adipose-derived stem 
cells, umbilical cord-derived stem cells, and pluripotent stem cells), and some methods to 
isolate and expand these cells have been developed aiming cardiac regenerative therapy.7,10–12 
In this field, stem cell-derived cardiomyocytes would facilitate the discovery of small 
molecules promoting cardiomyocyte differentiation that could be used for the activation of 
endogenous cardiac stem cells in clinical settings.12 
Stem cell autologous transplantation in patients is one of the candidates approach for 
efficient repair of impaired heart, due to the potential of stem cell populations (like cardiac 
progenitor cells (CPCs)) to promote cardiac regeneration and repair in experimental models 
and in patients with heart disease.2 Even so, there are complex and challenging 
pathobiological apprehensions. To make this possible, cell enhancement strategies need to be 
improved.13 For instance, patient derived cells undergoing a pre-treatment with small 
molecules or genetic modification which may contribute to an augmented recruitment of 
important factors which could enhance  differentiation or other beneficial functions.11 
 
I.2. STEM CELLS 
Stem cells are often described by their capabilities of self-renewal, to be progenitors of 
tissue or organ specific cells and their ability to functionally reconstitute a given tissue in 
vivo.14  
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These cells are present throughout the different developmental stages of an organism 
into and during the adult life and can be divided into two groups: embryonic and adult stem 
cells. Embryonic stem cells (ESC) are found only in the embryo and are classified as 
pluripotent, as they can give rise to any cell type of the three germ layers. On the other hand, 
adult stem cells are found in adult organisms, within fully differentiated tissues, and are 
classified as multipotent because they can only self-renew and differentiate into the different 
cells of the specific tissue where they reside or from which they were isolated. 
Pluripotent ESC are derived from the inner cell mass of the blastocyst. Unlike adult 
stem cells, ESC have a very high degree of self-renewal capability, at least in part due to the 
fact that they express high levels of telomerase.14 This property makes them hold great 
potential as cell-based therapies to promote vascularization and tissue regeneration.15 
At day 4 and day 7 to 10 of mouse and human development, respectively, cells of the 
blastocyst become lineage restricted, which means that they become committed to a germline 
and subsequently to a specialization within certain tissues. So, when working in vitro with 
ESC cells, we must to have in mind the need to maintain their pluripotency (preventing 
differentiation) and their self-renewal capacity using specific culture conditions.14,16  
In the field of cardiac regenerative therapy, it was shown that skeletal myoblasts 
extracted from patients themselves, have the potential to improve the function of a failing 
heart when they are transplanted into the heart as myoblast sheets17. However, these cells are 
not able to differentiate into cardiomyocytes, and therefore cannot replace the defective 
cardiomyocytes in a failing heart. A more likely efficient cell source in cardiac regenerative 
therapy could be if the transplantable cardiomyocytes could be prepared from ESCs.17,18 
 
I.2.1. DIFFERENTIATION 
Several strategies have been established to regulate the differentiation of ESC into all 
the three germ layers: the mesoderm, endoderm, and ectoderm.  
There are several methods that can be used to differentiate ESC towards a specific fate 
(Figure I.1). One of these methods is genetic manipulation, which force the expression of 
some transcription factors and can lead to direct differentiation of ES cells toward specific 
lineages. 
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Figure I.1 – Schematic overview of activation of endogenous multipotent cardiac stem cells by 
various means for myocardial repair. (A) Molecules (e.g. growth factors, cytokines), (B) 
noncardiac stem cells (e.g. bone marrow), (C) or gene therapy (e.g. micro-RNAs, gene transfer). 
Upon activation, resident endogenous cardiac stem cells can proliferate and mature into newly 
formed cardiac myocytes (yellow cardiac myocytes). 
 
For example, the overexpression of HOXB4, a gene involved in hematopoietic 
lineage, significantly enhances the hematopoietic potential of mouse ESC (mESC) 
differentiation in vitro. Expression of GATA-6 and GATA-4 genes, involved in myocardial 
differentiation and function, induces mESC differentiation into the extra-embryonic 
endoderm, while GATA-4 overexpression alone enhances cardiogenesis and markedly 
increases the number of terminally differentiated beating cardiomyocytes.19  
Another way to genetically control the differentiation of these cells is the use of micro-
RNAs, since a single miRNA can target multiple pathways simultaneously, being the effects 
on gene expression very powerful.20–22 Recently, a combination of microRNAs (miRNAs: 1, 
133, 208 and 499) has been identified as capable to reprogram murine fibroblasts to 
cardiomyocyte-like cells even though the efficiency rate being very low (about 1.5-7.7%).22 
The most recent study combined a subset of four transcription factors (Gata4, Hand1, Tbx5 
and myocardin) with two miRNAs (1, 133) to successfully reprogram human fibroblasts into 
cardiomyocyte-like cells. 23 
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The control of cell proliferation by growth factors, being often added to a medium to 
promote differentiation, is another approach that could affect survival of specific cell types. 
For instance, this direct differentiation can be implemented to overcome the heterogeneous 
cell mixture derived from differentiation cultures, and could be achieved by controlling the 
nutrient intake, the extracellular matrix (ECM), co-culturing with inductive cell types or 
adding a signaling molecule that have an impact on gene expression and cell proliferation.23 
However, the formation of ESC aggregates is the most widely used, consisting in the 
formation of suspended spherical aggregates called Embryoid Bodies (EBs).18 This structure 
facilitates multicellular interactions, in which cell-cell contact exists and gap junctions may be 
established. EB formation is stimulated in the absence of leukemia induced factor (LIF) from 
the culture media or mouse embryonic fibroblasts (MEFs) feeder layer, changing from two-
dimensional monolayer cell cultures to three-dimensional cell based structures in 
suspension.19,24 In the case of mESC, spherical ESC aggregates with morula-like structures 
formed in 2–6 days in suspension culture, and the removal of molecules which promote self-
renewal from the culture medium, combined with cellular aggregation is an efficient way to 
differentiate them.19,25  
 
 
I.2.2. CARDIAC DIFFERENTIATION 
The ability of ESC to differentiate into spontaneously contracting cardiomyocyte-like 
cells has attracted substantial interest from the scientific community. Initially it was a process 
considered difficult to control, but now cardiomyogenesis in vitro is a process which, to a 
certain extent, could be effectively manipulated and directed in the future.12  
Heart development involves a series of highly complex morphogenetic processes that 
are chronologically regulated by multiple phase-specific signals. The heart is the first organ to 
form in the embryo where its early function is essential to the circulation of nutrients and 
removal of waste. The construction of the heart is a complex process and involves the 
integration of different cell populations at distinct site as development proceeds.  
Using chicken and mice embryos as models it has been demonstrated that the heart 
tissue is composed of three major mesoderm-derived cell lineages: the cardiac myocyte, the 
vascular smooth muscle, and the endothelial cell lineages. Few days after fertilization, the 
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three embryonic layers form, the endoderm, the ectoderm, and the mesoderm. The primitive 
streak is formed from primitive endoderm and is the origin of many tissues, being cardiac 
progenitors formed in the posterior primitive streak.  
The cardiac mesoderm gives rise to the endocardium, the first heart field (FHF, which 
forms the atria, left ventricle, and the nodal conduction system), the secondary heart field 
(SHF, which forms the right ventricle, outflow tract, and part of the atria), and the 
proepicardial mesenchyme.26  
The generation of cardiomyocytes from pluripotent stem cells can be divided into four 
phases: formation of mesoderm, driving of mesoderm toward anterior mesoderm or 
cardiogenic mesoderm, formation of cardiac mesoderm, and finally the maturation of early 
cardiomyocytes. All of these steps are conducted by the expression of transcription factors, 
primarly T/Brachyury is expressed for primitive streak mesoderm, followed by Mesp-1 for 
cardiogenic mesoderm, and Nkx2.5, Tbx5/20, Gata-4, Mef2c, and Hand1/2 for cardiac 
mesoderm.12,27 
 
 
 
Figure I.2 – Diagram illustrating sequential steps in differentiation of pluripotent stem cells to 
cardiomyocytes. Pluripotent stem cells differentiate into early mesoderm cells, which further 
differentiate to cardiac mesoderm. Then, cells become committed to cardiac progenitors and 
differentiate to functional beating cardiomyocytes. The typical markers for each step are indicated.12 
 
Further identification of maturing cardiomyocytes could be done by the expression of 
cardiac structural proteins such as α-actinin, α-myosin heavy chain (α-MHC), and/or the 
cardiac isoform of Troponin-T (cTnT). Figure I.2 shows the sequential steps in the 
differentiation of pluripotent stem cells to cardiomyocytes.9,12  
There are several possible approaches for generating and expanding cardiomyocytes 
from major sources of starting cells like: induced pluripotent stem cells (iPSCs), adult heart-
derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts (Figure I.3).5,12,28 
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Besides their potential in clinical applications, these cells can offer more 
physiologically and clinically relevant reproducible human cell models than the ones 
presently available. Since they can offer the cardiac phenotype and the functional proper 
ties of the pluripotent stem cell-derived cardiomyocytes, they can be used as models to 
study early events of human cardiogenesis and have the potential to be used in pharmaceutical 
drug discovery and safety toxicology.12 
A genetic manipulation approach, like reprogramming somatic cells into cardiac 
lineage cells, bypassing the pluripotent state, is another possibility. Human embryonic stem 
cells (hESCs), and the recent discovery of iPSCs generation, have attracted the curiosity of 
many investigators regarding the potential of these cells, trying to develop strategies to 
efficiently and reliably direct stem cell differentiation into the cardiovascular lineage. 5  
Differentiation of cardiomyocytes from hESCs has progressed rapidly through a 
growth factor-mediated approach of Srivastava group, who showed successful direct 
conversion of fibroblasts into cardiomyocyte-like cells in vitro and in vivo by a specific 
combination of cardiac transcriptional factors (Gata4, Mef2c, and Tbx5). 2,25 
 
Figure I.3 – Schematic representation of different stem cell sources for cardiac regeneration. 
ESCs/iPSCs can be generated by reprogramming fibroblasts and then differentiated into cardiac 
lineages. Another of the approaches rely on the direct conversion of mature somatic cells (like 
fibroblasts) into other mature cell types like cardiomyocytes or to an intermediate stage between full 
pluripotency and total maturity: a cardiac progenitor stage.21 
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Also, Itskovitz-Eldor et al. (2000)29 have demonstrated that contracting 
cardiomyocytes can be generated from of hPSCs opening the possibility of producing an 
unlimited number of human cardiomyocytes to rebuild the heart. These advances in 
embryology and hPSC differentiation have offered significant insights into the mechanisms of 
cardiopoiesis, building a promising future regarding the repair of injured hearts through 
clinical applications of these cells. 5,29 
Although the efficiency of differentiation protocols has increased over time, there are 
some disadvantages using this type of method. One of them relies on the optimization of the 
methods used, to obtain a better efficiency.  Another concern is the fact that a possible risk of 
viral transduction-mediated tumorigenesis could occur, making this method not the safest 
one.2,25 
Another alternative source of de novo cardiomyocytes is the direct reprogramming of 
cardiac fibroblasts and other adult cell types into cardiomyocytes using cardiac-specific 
transcription factors: Gata4, Mef2c, and Tbx5.30 Using this approach, reprogramming cardiac 
fibroblasts in vivo for heart regeneration becomes a possibility, with direct application of 
these transcription factors.5 
Ultimately, the derivation of cardiomyocytes without viral integration is essential for 
the generation of safe cells for therapeutic applications, and to avoid genetic manipulation. 
Therefore the production and application of recombinant proteins constitute an alternative for 
the over-expression of a desired gene. 
 
 
I.3. CITED2 
CITED2 is a CREB-binding protein (CBP)/p300-interacting transactivator with 
glutamic acid (E) and aspartic acid (D) enriched tail, previously named melanocyte-specific 
gene-related gene (MRG)1/p35srj. This gene locates within the 6q23 region in humans and it 
encodes a nuclear protein which is ubiquitously expressed, and binds directly, and with high 
affinity, to the first cysteine–histidine-rich (CH1) region of p300 and CBP, being present in 
all vertebrates.31–33 
 As a CBP/p300-dependent transcription factor, CITED2 regulates gene transcription 
by interacting with other transcription factors acting as a co-activator or a co-repressor. 
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Several studies have shown that variations/mutations or abnormal methylation of the CITED2 
gene are related with congenital heart defects.34,35 
In mouse, CITED2 is essential for normal development, since disruption of the gene is 
embryonic lethal. When CITED2 is not expressed in mice, the embryos die in utero with 
cardiac and aortic arch malformations, adrenal gland agenesis, small cranial and dorsal root 
ganglia, exencephaly, neural crest and left-right patterning defects.32,36 The cardiac 
malformations are various, such as atrial and ventricular septal defects, double outlet right 
ventricle, common arterial trunk, transposition of the great arteries, interrupted and aberrant 
aortic arches and others. 35,37–39  
CITED2 is essential at two different times of mESC fate, first maintaining ESC in 
pluripotency state via direct regulation of a number of activated signaling pathways that 
control the expression of the transcription factors Oct4, Sox2 and Nanog, and then leading to 
differentiation towards cardiomyocytes. 35,40 
Interestingly, a shift of the expression levels of these core pluripotency master 
regulators from their optimal expression prompt ESC to differentiate. Therefore, the 
maintenance of pluripotency depends on the stringent control of their expression by forward 
and feedback regulation loops.35 Studies supported this hypothesis, since the overexpression 
of CITED2 in mESC sustains self-renewal of these cells, even in the absence of LIF.36,41 One 
of the possible explanations is the fact that CITED2 is a direct target of FoxP1 which 
mediates pluripotency in mESC, and could be involved in the maintenance of fetal and adult 
hematopoietic stem cells. In contrast, the absence of CITED2 during mESC differentiation 
leads to a delay in self-renewal genes activating hematopoietic, neuronal and cardiac 
differentiation pathways. 40,42 
Recent work developed in our group showed that CITED2-depletion at the onset of 
differentiation significantly impairs the generation of cardiomyocytes and decreases the 
expression of early mesoderm markers (Brachyury, Mesp1), pro-cardiogenic transcription 
factors (Isl1, Gata4, Tbx5) and secreted molecules (Wnt5a and Fgf10). In opposition, CITED2 
overexpression is sufficient to stimulate the expression of these genes in undifferentiated ESC 
and to promote cardiac differentiation. Finally it was shown that CITED2 expression is highly 
associated with Cardiac Progenitor Cells (CPC) populations, particularly cardiac progenitors 
of the SHF marked by Isl1 expression (Manuscript in preparation: Cited2 synergizes with Isl1 
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and promotes cardiac differentiation of mouse embryonic stem cells;  Ivette Pacheco-Leyva, 
A. Matias, D. Oliveira, Rita Nascimento, V. Afonso, JMA Santos, E. Guerreiro, Anna C. 
Michell, Annebel M. van De Vrugt, G. Oliveira, K. Kranc, G. Ferreira, I. and J. Bragança). 
 
 
I.4. RECOMBINANT PROTEINS 
Intracellular delivery of biological macromolecules is a major topic in the field of drug 
delivery, since many biological macromolecules, like proteins, peptides, and nucleic acids, 
have proven to be useful for the treatment of various health problems.43 
However, the delivery of macromolecules to their target sites is not easy, mostly due 
to the structure of the eukaryotic cell membrane structure. The plasma membrane consists of a 
lipid bilayer in which proteins and glycoproteins are inserted, and their hydrophobic nature 
makes the delivery of proteins less efficient, since it prevents the hydrophilic compounds to 
cross the membrane. 25,44 
One of the systems that can be used to overcome the problem of the entry into the 
cells, is the application of protein transduction domains (PTDs), also known as cell-
penetrating peptides (CPPs). These kind of peptides are capable of transporting cargo across 
the membrane and delivering biologically active proteins inside the cell (Figure I.4). Besides, 
they can be linked to another cargos such as peptides, proteins, oligonucleotides, pDNA, or 
liposomes.25,43,45  
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Figure I.4 – Schematic representation of cargo variety covalently linked to arginine-
dependent protein transduction domains (PTDs). Adapted from 46. 
 
The initial discovery of PTDs was originated from the independent observation by 
Green and Frankel in 1988, when a special aminoacid sequence derived from HIV-1 TAT 
protein, the TAT PTD, showed that could penetrate cells in a receptor-independent, 
concentration-dependent and activate HIV-1-specific target genes. That peptide could 
translocate across the plasma membrane by its 11 basic aminoacids (residues 47–57) and to 
deliver heterogeneous proteins into cells. 25,47–50 This PTD has a higher efficiency for protein 
delivery into the cells when compared to other PTD signals.25 
Once added to the culture media, TAT-mediated transduction occurs through a rapid, 
temperature and energy-independent process, suggesting direct penetration across the lipid 
bilayer because of the strong binding of the PTD to the cell surface. 50  
One of the hypothesis for the capacity of translocation of these kind of molecules is 
that their positive charges allow the protein to interact with lipid rafts in a membrane which is 
negatively charged. That way it can overcome the cell membrane barrier by different 
mechanisms, like macropinocytosis.25,47,49  Endocytosis was later suggested as an alternative 
internalization pathway. It is now thought that endocytosis and direct translocation are two 
coexisting pathways.51 In all cases, after endocytic uptake, the internalized CPPs (either alone 
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or linked to cargos) should escape from the endocytic vesicles to the cytosol to avoid 
degradation.43 Within cells, the TAT-fusion proteins are either degraded or refolded by the 
cellular machinery into functional proteins.49  
One of the characteristics of the TAT PTD sequence which seems to be responsible for 
the transduction of these proteins is the enrichment by arginine (R) residues and that the 
sequences with 6-12 consecutive R residues are functional PTDs.47 These kind of arginine-
rich cell-penetrating peptides (AR-CPPs) are the most widely studied.43  
These oligoarginine peptides present differential manners of internalization and 
cellular localization depending on the number of arginine residues in the molecules. For 
example, a tetramer of arginines (4R) did not show significant internalization, while an 
octamer (8R) showed efficient internalization and nuclear localization, very similar to that of 
TAT. Conversely, a larger number of residues of arginine did not result in an increased 
internalization capability, as an hexadecamer of arginines (16R) showed less efficient 
internalization compared to TAT, without showing significant nuclear localization.52 
The transduction of these PTD-based proteins showed to be very efficient working for 
virtually all types of cells tested. The localization of transduced proteins within the cells 
depends on the nature of imported proteins, the cell type used and delivery approach.47 
In 2009, Zhou et al. reported the successful reprogramming of mouse somatic cells to 
pluripotency using recombinant proteins of 11R-Sox2, 11R-Oct4, 11R-Klf4 and 11R-c-Myc. 
Kim et al.(2009) also reported the successful induction of pluripotency in human fibroblast 
cells using 293T cell extracts that contained the same four reprogramming factors (RF) with 
the application of a polyarginine peptide C-terminal 9R PTD. 47,53–55 
Following the same point of view, Zhang et al. (2012) used reprogramming factors 
fused with TAT (TAT-RFs) or 11R to induce human foreskin fibroblast and reprogrammed 
these cells to iPSCs with success. The RFs used were the same as the mentioned by previous 
groups and one more, Nanog, and all of them were added to the culture medium. Comparing 
the efficiency of transduction between TAT and 11R, it was found that they were almost the 
same. However, regarding the reprogramming efficiency, TAT-RFs presented better results 
than 11R-RFs.47 
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Concerning the use of recombinant proteins in cardiac differentiation, Fonoudi and 
collaborators (2013) developed a recombinant protein which was added to hESCs cultures, 
and efficiently penetrated into the cells, enhancing the differentiation into cardiac cells. To do 
this, they developed a transduction system based on the fusion of TAT with Islet1 (Isl1). Isl1 
is a marker of myocardial lineage during mammalian cardiogenesis and marks a common 
population of progenitors in the heart that can differentiate into cardiomyocytes, smooth 
muscle and endothelial cells. The intent was to improve the cardiomyocyte differentiation rate 
under a suspension culture condition and they have successfully demonstrated that the 
application of TAT-ISL1 increased the differentiation of cardiomyocytes (2–3 folds) without 
genetic modification.25 
Since this method lacks of genetic manipulation, these kind of molecules can be easily 
applied in drug discovery or cell therapy since the risk for the application is diminished.  
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II. AIMS OF THE PROJECT 
 
In this thesis, it was proposed to combine TAT and an arginine-rich peptide 
(composed by 8 arginines) with a human protein – CITED2 – which is involved in cardiac 
differentiation, to evaluate the transduction into mESC. 
 
The specific aims of this study were the following: 
- Cloning of two different PTDs into a pGEX vector and sequential cloning of the 
CITED2 gene 
- Production and purification of GST-3C Protease cleavage protein 
- Overexpression of recombinant proteins in E.Coli  
- Purification and cleavage of the recombinant proteins 
- Assessment of proteins functionality through their capacity to rescue Cited2 knockout 
mESCs cardiogenic defects 
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III. MATERIALS AND METHODS 
 
This practical work aimed the synthesis and application of recombinant proteins to 
mESC. The process is not simple and involved many phases, since the DNA cloning to the 
direct application of the protein to the stem cells. 
 
 
Figure III.1 – Schematic representation of the work developed in course of this thesis. 
 
 
 
III.1. MOLECULAR CLONING 
Gene cloning is a complex process that requires several DNA techniques, in which a 
desired fragment of DNA is inserted in a cloning vector, such as a plasmid, in order to 
increase the number of copies of the fragment of interest. This is usually achieved by inserting 
the vector in a host, being the most commonly used bacteria. 
This can be done with enzymes which are used to excise the fragments of interest and 
the same enzymes to open up the plasmid. After obtaining the DNA from the vector and the 
desired fragment, another enzyme will be needed to integrate the fragment in the host genome 
(ligation).  
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The aim for our final cloning was to obtain CITED2 linked to TAT and 8R in a pGEX 
vector which will permit the further purification of the proteins, so we needed to do four 
subclonings into the pGEX-6P-1 vector (Amersham Biosciences): 
- Insertion of TAT 
- Insertion of 8R 
- Insertion of CITED2 into each one of the created vectors 
 
 
Figure III. 1 - Schematic representation of sequential fragment cloning into pGEX-6P-1 
vector. 
 
The pGEX-6P-1 vector (Appendix 1) was the expression vector chosen and is 
designed to express a Glutathione S-Transferase (GST) tag fused to the N-terminal of the 
protein of interest through a short peptide chain containing a specific endoprotease cleavage 
site. GST tag will allow the binding of the fusion protein to glutathione affinity columns for 
subsequent purification. This vector has a T7 promoter system, which is similar to the lac 
operon in E. coli and, being Isopropyl β-D-1-thiogalactopyranoside (IPTG) sensitive, so when 
IPTG is added to the culture medium, the transcription of protein linked to GST is induced. 
For bacterial selection, it has a Ampicillin (Amp) resistance gene. 
 
 
III.1.1. RESTRICTION ENZYME DIGEST 
A restriction enzyme is a naturally occurring bacterial endonuclease that allows to cut 
a DNA sequence, recognizing a specific nucleotide sequence also known as restriction site. 
This method have turn out to be the most widely used method to selectively transfer a specific 
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gene or a DNA sequence from one plasmid to another when the size of the plasmid insert is 
known. Another application is when the size of the plasmid insert and vector backbone are 
known, this technique can be used to verify and confirm the construct (diagnostic digest). 
To diagnostic digests, the samples were prepared accordingly with Table 1, at 37ºC 
for 1h. To isolate inserts, samples were also prepared in the same way but the digestion was 
performed O.N. (overnight) at 37ºC. 
 
Table 1 – Reaction mix used for the usual restriction digestion of the pDNA. 
 
Reagent Volume 
DNA x µL (1 µg) 
Enzyme 1 1 µL 
Enzyme 2 1 µL 
Buffer 10X 5 µL 
MilliQ H2O Up to 50 µL 
Total 50 µL 
 
To perform the restriction enzyme digest the double stranded DNA has to be incubated 
with the appropriate restriction enzymes in a suitable buffer recommended by the supplier. 
For this work, we performed several digestions to accomplish different goals: 
- Double digestion of pGEX-6P-1 with BamHI and EcoRV to check the quality and 
purity of the plasmid 
- Digestion of pGEX-6P-1 with BamHI to insert TAT and 8R  
- Double digestion of pGEX-6P-1+TAT (pGEXT) with SacII and PstI to check if 
cloning of TAT was successful 
- Double Digestion of pGEX-6P-1+8R (pGEXR) with BamHI and PstI to check if 
cloning of 8R was successful 
- Double Digestion of pGEXT with BamHI and XhoI to insert Cited2  
- Double Digestion of pGEXR with BamHI and XhoI to insert Cited2 
- Double Digestion of pGEXTC2 and pGEXRC2 with BamHI and XhoI to check if 
cloning of Cited2 was successful. 
The enzymes used in this work and the appropriate buffers are listed in Table 2. 
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Table 2 – List of restriction enzymes used for digestions, with their recognition site and optimal 
conditions. 
Enzyme Recognition site Temperature Concentration Producer 
BamHI 5’…G▼GATCC…3’ 37ºC 10 units/μL Fermentas 
EcoRV 5’…GAT▼ATC…3’ 37ºC 10 units/μL Fermentas 
SacII 5’…CCGC▼GG…3’ 37ºC 10 units/μL Takara 
PstI 5’…CTGCA▼G…3’ 37ºC 10 units/μL Promega 
XhoI 5’…C▼TCGAG…3’ 37ºC 10 units/μL Fermentas 
 
 
Buffers were selected considering the enzymes used. In the case of double digestion, 
the buffer was selected considering the best activity for both enzymes chosen. 
 
 
III.1.2. AGAROSE GEL ELECTROPHORESIS 
Gel electrophoresis is a standard method in molecular biology used to separate 
molecules accordingly with their size (in this case by length in base pairs) for visualization 
and purification. Applying an electric charge, negatively charged DNA move through an 
agarose gel matrix towards a positive electrode. This way, smaller molecules move faster than 
larger molecules, because they migrate more easily through the matrix. 
This process was made to check the DNA from the vector, to purify the desired 
fragments or to know if the clonings were successful. 
For each run was prepared a fresh 1% TAE-gel by dissolving the agarose powder into 
TAE buffer in a microwave for about 1 to 3 min (see composition at Table 3). After it cooled 
down for 5 min, GreenSafe (NYZTech, Portugal) was added, and the molten agarose was 
poured into the flat mold for hardening. A comb was placed to form wells for running the 
samples and let the agarose gel solidify for at least 30 min, removing carefully the comb 
before the run.  
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Table 3 – Composition of 1% TAE agarose gel. 
Agarose Gel 
Agarose 0.5 g 
TAE 1X 50 mL 
GreenSafe 2 µL 
 
 
 The gel was then transferred into an electrophoresis unit filled with TAE-buffer. 
Samples were previously prepared with loading buffer (Orange Loading dye 6X) accordingly 
with Table 4, and carefully loaded into the wells along with a ladder mix (GeneRuler DNA 
Ladder Mix, Thermo Scientific), under a constant electric potential of 120 V for 40 min.  
The posterior visualization of DNA bands was performed in ChemiDoc XRS 
Molecular Imager (Bio-Rad). 
 
 
Table 4 – Sample preparation prior agarose gel electrophoresis. 
 
DNA Sample 
DNA 20 µL 
Orange Loading Dye 6X 3 µL 
 
 
III.1.3. GEL PURIFICATION 
Gel purification is the method that allows to isolate and purify DNA fragments after a 
standard agarose gel electrophoresis, cutting out the DNA bands which had the expected size 
of the agarose gel and executing several steps to purify the DNA samples. 
In this work, we performed this method for several occasions: to isolate the plasmid 
vector pGEX-6P-1 DNA digested with BamHI, the pGEX-6P1+TAT and the pGEX-6P1+8R 
digested with BamHI and XhoI, and also CITED2 DNA insert from a preexisting plasmid 
(pSB54), digested with BamHI and XhoI. All the purifications were performed using 
GeneJETTM Gel Extraction Kit from Fermentas.  
Purification was carried out according to the manufacturer’s instructions. In summary, 
the excised fragments were placed in centrifuge tubes and weighted. For each 100 mg of 
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agarose gel, 100 µL of binding buffer was added, then the mix was incubated at 50-60ºC for 
10min, inverting the tube a few times. The binding of DNA was performed by transferring the 
solution to a column, which was placed in a collection tube (provided by the kit). The sample 
was centrifuged for 1 min at 12000g and the flow-through discarded. Then, 700 µL of Wash 
Buffer were added to the column and centrifuged in the same conditions, being the flow-
through also discarded. The centrifugation was repeated but with the empty column. 
Afterwards, the column was placed in a fresh 1.5 mL centrifuge tube and 50 µL of Elution 
Buffer was added to the column, which allowed the sample to be obtained after a 
centrifugation for 1 min at 12000g. 
 
 
III.1.4. DEPHOSPHORILATION  
One of the steps prior to the ligation of fragments to the vector, is dephosphorilation. 
This process will avoid self-closure after the restriction digestion since the pDNA become 
linearized.  
To achieve that, 1 µL of Calf Intestine Phosphatase (CIP) (Finnzymes, Thermo 
Scientific) was added to the DNA obtained, mixed and incubated for 30 min at 37 ºC in a dry 
bath (CH-100, Heating/Cooling Dry Block, Biosan). After this time, the tubes needed to be 
submitted to heat inactivation of the enzyme, leaving it at 65ºC for 30min, to ensure that the 
enzyme would not interfere in the ligation reaction. 
 
 
III.1.5. LIGATION REACTION 
After restriction of the inserts and the vector, and subsequently dephosphorilation of 
the last, the ligation reactions were performed in order to the inserts to be integrated into the 
host vector (Table 5). For the ligation to happen, both DNAs needed to be incubated with an 
enzyme – T4 DNA ligase (Fermentas) – and its buffer (10X T4 Ligase Buffer, Fermentas), for 
at least 2 hours (sometimes it was necessary to extend the time to 4 hours) at Room 
Temperature (RT). 
TAT and 8R DNA fragments were already prepared by professor J.Bragança (primers 
used are listed in Table 6). Both set of oligonucleotides encoding TAT or 8R were chemically 
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synthetized to harbor, after annealing, a BglII hemi-site at their 5’ end and a BamHI site at 
their 3’ end flanking the TAT or 8R sequence. The BglII hemi-site can hybridize a BamHI 
hemi-site, however the resulting BglII/BamHI composite site can no longer be digested by 
neither of these enzymes. Since these oligonucleotides were synthetic, their 5’ extremities 
were phosphorylated with a T4 polynucleotide kinase in the presence of ATP before the 
annealing. 
 
Table 5 – Ligation mix components.  
 
 
 
 
 
 
 
 
 
Table 6 – Gene primers used in to prepare TAT and 8R inserts. 
 
Gene Forward 5’-3’ Reverse 5’-3’ 
TAT 
GATCTGGCTACGGCCGCAAGAAACGCC
GCCAGCGCCGCCGCGGTG 
GATCCACCGCGGCGGCGCTGGCGGCGTT
TCTTGCGGCCGTAGCCA 
8R 
GATCTGGCCGCCGCCGCCGCCGCCGCCG
CCGCCGCCGCCGCGGTG 
GATCCACCGCGGCGGCGGCGGCGGCGG
CGGCGGCGGCGGCGGCCA 
 
After ligation procedure, 5 µL of cloned DNA was used to transform chemically 
competent E. coli cells.  
 
 
III.2. PREPARATION OF CHEMICALLY COMPETENT CELLS 
Competent cells are bacterial cells that possess more easily altered cell walls by 
which foreign DNA can be passed through easily. The majority of cells cannot take up DNA 
efficiently unless they have been exposed to special chemical or electrical treatments to make 
them competent. 
Reagent Volume 
10X T4 Ligase Buffer 1 µL 
pGEX-6P-1 3 µL 
Insert 5 µL 
T4 DNA ligase 1 µL 
MilliQ H2O Up to 10 µL 
Total 10 µL 
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In this work E. coli cells were subjected to chemical treatment, where they were 
treated with high cation concentration (in this case MgCl2) and then exposed to a heat shock 
which makes the cell membrane to become permeable for plasmid DNA.  
Cultures were grown in 25 mL of Lysogeny Broth (LB; 10g/L Tryptone, 5g/L Yeast 
Extract, 10g/L NaCl, pH 7.0) medium at 37ºC in an orbital shaker (Agitorb 200 IC, Aralab®) 
until they reach an O.D.600nm of 0.47. Cells were harvested by centrifugation at 1000 g for 10 
min (Centrifuge 5810R, Eppendorf®), discarding supernatant. Accordingly with culture 
volume, cells were resuspended in 1/10 (v/v) of ice cold TSS buffer, previously prepared 
(10% Polyethylene glycol 8000, 5% Dimethyl Sulfoxide, 20 mM MgCl2 and 85% autoclaved 
LB, pH 7.0), and incubated on ice for 10 min. Cells were either used immediately or frozen in 
100 µL aliquots. 
 
 
III.3. TRANSFORMATION OF COMPETENT CELLS 
Transformation is the process where foreign DNA (like plasmids) is introduced into a 
bacterial cell. This process is very common and useful since it allows the replication of a 
specific plasmid DNA. The majority of the plasmids carry a gene for antibiotic resistance 
which can be used as a selection tool. 
However, not all bacteria strains can be transformed, so they need to enroll a process 
to become competent, which makes their cell walls more likely to uptake DNA (see section 
III.2). 
The bacterial cells used in this study were from the strain E.coli DH5α (for cloning) 
and BL21(DE3) (for protein expression), previously made competent. All the transformations 
were performed using the heat-shock method. 
In cloning, bacteria was transformed by adding 5 µL of the ligation mix to 50 µL of 
DH5α and incubated on ice for 30 min. Further the sample was incubated at 42ºC for 1 min 
and placed on ice for 2 min. To make the cells recover from the heat shock, 250 µL of Super 
Optimal broth with Catabolite repression (SOC) were added to the cell suspension and 
incubated at 180 rpm, at 37ºC for 1 hour in an orbital shaker (Agitorb 200 IC, Aralab®). 
Bacteria were plated in LB agar plates with Amp (100µg/mL) and placed inverted on the 
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incubator at 37ºC O.N. For the usual transformation with purified and amplified DNA 
(miniprep, midiprep or protein expression), only 1 µL was needed to make the transformation.  
When the colonies were the result from a ligation reaction transformation, we checked 
if the plasmid was well constructed, by purifying pDNA, double digesting it and analyzing the 
result by electrophoresis. 
 
 
III.4. EXTRACTION OF DNA  
III.4.1. MINIPREP 
In order to extract the pDNA from the recombinant bacteria, to check by 
electrophoresis if the inserts were cloned in the right way to the cloning vector, the 
GeneJET™ Plasmid Miniprep (Thermo Scientific) was used. 
Several colonies were isolated and transferred from the plate into a 2 mL LB medium, 
supplemented with Amp (100 µg/mL) and incubated O.N. at 37ºC, with agitation (200 rpm).  
To perform the extraction, cultures were placed in a clean and sterile microcentrifuge 
tube, and spun down at 6800 g for 2 min being the supernatant discarded. To the pelleted cells 
250 µL of Resuspension Solution (which contained RNase A) was added and a micropipette 
was used to resuspend the cells. Then 250 µL of Lysis Solution was used to disrupt the 
bacterial walls, being the solution mixed by inversion, making the solution clear and viscous. 
A volume of 350 µL of Neutralization solution was added to the mix, and the tube was 
inverted 4 to 6 times. The mixture was centrifuged at 14000 g for 10 min (Centrifuge 5810R, 
Eppendorf®).  
The supernatant was transferred carefully to a fresh tube (avoiding the white 
precipitate) using a micropipette and applied to the Thermo Scientific GeneJET Spin Column. 
The columns were then centrifuged for 1 min and the flow-through was discarded, since the 
plasmid DNA binds to the column in this step. Then 500 µL of Wash Solution were added to 
the column to wash it and the column was centrifuged again for 1 min, being the flow-through 
discarded. This step was repeated one more time. The empty column was centrifuged for an 
additional 1 min to remove residual wash buffer. 
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Finally, the column was placed in a clean 1.5 mL microcentrifuge tube and the DNA 
was eluted by incubation in 50 μl Elution Buffer for 2 min and centrifugation for 2 min.  
Once resuspended, the samples were quantified by spectrophotometry with NanoDrop 
2000 spectrophotometer (Thermo Fisher Scientific Inc, USA) and stored at -20ºC until further 
use. 
Clonings which seemed to be successful were sent to StabVida for sequencing 
(plasmid maps and sequencing results at Appendix 2 and 3). Once the identity of the cloned 
fragments was confirmed, a larger scale preparation of plasmid DNA was required. To 
achieve this goal, midiprep was performed. 
 
 
III.4.2. MIDIPREP 
In the various stages of this experimental work several DNA constructs needed to be 
purified such as pGEX-6P-1 vector for the preparation of the ligation reactions, and/or 
extraction of various products of ligation reactions for the sequencing. 
To obtain the plasmid DNA, the QIAGEN
® 
Plasmid Midi Kit was used according to 
the manufacturer’s instructions. 
Previously, E. coli was transformed with the desired DNA and the day after, a colony 
was picked and inoculated in 100 mL of LB medium supplemented with Amp (100 μg/mL), 
allowing growth to occur O.N. at 37ºC in an incubator with agitation (200 rpm). 
Cell suspension was then transferred to 50 mL conical centrifugal tubes and 
centrifuged for 15 min at 6000 g, at 4ºC. Supernatant was discarded and the pellet 
resuspended with 4 mL of Buffer P1 (which contained RNase) until no cell clumps were 
visible. After, 4 mL of Buffer P2 was added and all components were mixed thoroughly by 
inversion and incubated for 5 min at RT. Buffer P3 was prechilled and 4 mL were added to 
the suspension, mixed by inversion and incubated on ice for about 15 min. The sample was 
centrifuged for 30 min at 4ºC at 18000 g (Centrifuge 5810R, Eppendorf®).  
Meanwhile, the resin column (Qiagen-tip 100) was assembled and needed to be 
equilibrated in a suitable buffer which was provided by the kit. A volume of 4 ml of Buffer 
QBT was added to the column and let through the column, being the flow through discarded. 
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Supernatant was transferred to the column and the solution was allowed to pass 
through the resin by gravity flow, discarding the flow-through.  
For the washing step, 10 mL of Buffer QC was added to the column and once again 
passed within the column by gravity flow, being the flow through discarded. This step was 
repeated one more time. 
The columns were transferred to fresh 15 ml conical centrifuge tubes and 5 ml of 
Buffer QF were added to release pDNA from the resin. Columns were discarded and 3.5 mL 
of isopropanol were added to the flow-through, being the solution mixed and centrifuged at 
15000 g for 30 min at 4ºC. Supernatant was discarded, and 1 mL of 70% ethanol was used to 
wash the pellet, and the solution was transferred to a 1.5 mL centrifuge tube. The following 
step was a centrifugation at 15000 g, at 4ºC, for 10 min. Supernatant was discarded once more 
and pellet was allowed to dry at RT until no ethanol was visible.  
Plasmid DNA was resuspended in 250 µL of TE buffer, and the sample was submitted 
to NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific Inc, USA) measurement in 
order to check the DNA concentration and stored at -20ºC until further use. 
 
 
III.5. RECOMBINANT PROTEIN PRODUCTION  
Plasmids were obtained ant they were used to transform E. coli BL21 (DE3) for 
expression of the proteins. 
BL21(DE3) strain was chosen for the fact that is the most widely used host for target 
gene expression, because it has good characteristics such as protease deficiency, solubility 
enhancement and others. This strain with DE3, a λ prophage, carries the T7 RNA polymerase 
gene and the lacIq. Expression of T7 promoter containing plasmids is repressed until induction 
of IPTG or Lactose. 
 
 
III.5.1. PRODUCTION OF GST-8R-C2 AND GST-TAT-C2 PROTEINS 
The day after transformation of the cells, a colony was picked from the plate and 
inoculated in 50 mL of LB medium (with Amp) O.N., 37ºC at 180 rpm. 
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Next day, O.D.600nm was measured in a spectrophotometer (Pharmaspec UV-1700, 
Shimadzu) and the volume necessary to reach an O.D.600nm of 0.1 was diluted into 500 mL of 
LB medium (with Amp). Culture was incubated with shaking (180 rpm) until O.D.600nm 
reached 0.6-0.8, and at that point 0.2 mM of IPTG was added to the culture. The incubation 
continued for 4 hours in the orbital shaker but at a lower temperature (20ºC) at 180 rpm. 
Samples of 1 mL were collected before and after induction by IPTG to be analyzed by 
Sodium Sodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-Page) and confirm the 
expression of the protein of interest. 
Culture was transferred for containers which allowed to centrifuge that kind of volume 
in a swing-bucket rotor at 4000 rpm for 20 min at 4ºC. Supernatant was discarded and pellet 
was stored at -80ºC until purification procedure. 
 
 
III.5.2. PRODUCTION OF GST-3C PROTEASE 
GST-3C is a fusion protein of GST and human rhinovirus 3C protease.  
The protease specifically recognizes the amino acid sequence Leu-Glu-Val-Leu-Phe-
Gln▼Gly-Pro, cleaving between the Gln and Gly residues. Since the protease is fused to GST, 
it is easily removed from cleavage reactions using Glutathione Sepharose. This protease is 
maximally active at 4°C, and when cleavage is performed, it should be done at low 
temperatures, improving the stability of the target protein. 
Plasmid DNA for the production of GST-3C was a gift from Dr Kamel El Omari, 
University of Oxford. For this protein, the production procedure was similar to the one of 
GST-8R-C2 and GST-TAT-C2 described before (see section III.4.1), and the differences rely 
on the concentration of IPTG applied to the medium (0.5 mM in this case), and the incubation 
time after induction (O.N. instead of 4 hours). 
 
 
III.6. SDS-PAGE 
SDS-PAGE (Sodium Sodecyl Sulphate-Polyacrylamide Gel Electrophoresis) is 
commonly used method to separate protein-mixtures according to their molecular weight, 
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based on their differential rates of migration through a matrix (a gel) under the influence of an 
applied electrical field. SDS, an anionic detergent, is added to the protein solution to linearize 
the protein, to cover the intrinsic charge of the different proteins and to apply a constant 
negative loading per unit mass. Additionally all samples are heated to 95 °C for 5 min for 
better linearization and denaturing of the proteins.  
The velocity of the proteins depends on ionic strength, viscosity of the gel and 
temperature. A molecular weight marker (ladder) has to be added to determine the molecular 
mass of the proteins.  
This technique was used to monitor two situations: if the induction of the protein 
production with IPTG in BL21 (DE3) was done successfully, and to evaluate the fractionated 
samples after the purification process.  
Accordingly with the nature of samples, they were prepared to run on the gel with 
different methods. The collected samples (1 mL) from the bacterial growth, before and after 
induction with IPTG, were centrifuged at 8000 rpm for 10 min at 4ºC (supernatant was 
discarded). Pellet was then resuspended in SDS loading buffer 1X accordingly with samples 
absorbance at the time they were collected, and this way they could be compared in the gel. 
The samples from the purification process, were prepared in different ways (see Table 7), 
since the insoluble fraction (InsF), soluble fraction/injected sample (SF), flow-through (FT) 
and Wash were more concentrated comparatively with the digested and the eluted samples 
from the column. 
 
Table 7 – Sample preparation prior SDS-Page electrophoresis. 
 
InsF (µL) 
SF  
(µL) 
FT  
(µL) 
Wash (µL) 
Digested/Eluted  
(µL) 
Sample 5 5 5 5 20 
MilliQ H2O 15 15 15 15 - 
4X Loading Buffer  5 5 5 5 5 
 
 
Since proteins are mostly colorless, to monitor the expression of the protein we used a 
staining method which consists in the immersion of the gel in Coomassie Brilliant Blue 
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solution (10% acetic acid, 25% methanol, 0.2% Coomassie Brilliant blue G250) and 
subsequent destaining. 
In the case of the results of purification process we used the Coomassie Brilliant Blue 
solution and Western Blot to confirm the identity of the protein. 
Therefore, for each run an acrylamide gel need to be prepared, and it was composed 
by two parts: the stacking gel and the resolving gel (Table 8). Stacking gel is buffered by 
Tris-HCl at pH 6.8, while the resolving gel is also buffered by Tris-HCl but at pH of 8.8. The 
stacking gel has a low concentration of acrylamide and the resolving gel a higher 
concentration capable of retarding the movement of the proteins. 
 
Table 8 – Composition of each layer of a 12% acrylamide SDS-Page gel. 
 
Resolving gel 
(12% acrylamide) 
Stacking gel 
(5% acrylamide) 
MilliQ H2O 2.15 mL 1.45 mL 
1.5 M Tris (pH 8.8) 1.25 mL - 
1 M Tris (pH 6.8) - 0.25 mL 
Acrylamide 40% 1.5 mL 0.25 mL 
10% SDS 50 µL 20 µL 
10% APS 50 µL 20 µL 
TEMED 5 µL 2 µL 
 
 
After the gel being polymerized and placed in a electrophoresis unit Mini Protean 3 
(Bio Rad), a running buffer solution (25 mM Tris, 250 mM glycine, 0.1% (m/v) SDS, pH 8.3) 
was poured into the unit, and the samples were loaded into the wells as long as 2.5 μL of a 
proper molecular weight marker of a ladder (PageRulerTM Prestained Protein Ladder, 
Fermentas Life Sciences). 
The runs were performed at 140 V during approximately 2 hours. After the run, the gel 
was stained O.N. with Coomassie Brilliant Blue solution at RT and then in destaining solution 
(40% methanol, 10% acetic acid and 50% of MQ H2O) until the gel is colorless except bluish 
protein bands, and kept in MilliQ H2O. 
 
Materials and Methods 
29 
III.7. PROTEIN PURIFICATION 
III.7.1. GST-3C PROTEASE 
Frozen pellet was thawed on ice and resuspended in 5 mL of ice cold Phosphate 
Buffered Saline (PBS) 1X, with 1mM of Dithiothreitol (DTT) and 1 mM of 
phenylmethylsulfonyl fluoride (PMSF). Sample was then sonicated on ice for a total time of 1 
min (On 7’’, Off 10’’ cycle, amplitude of 60%) in a ultrasonic processor (VCX 130, 
VibraCell). Centrifugation was performed at 18000 g for 40 min at 4ºC to pellet debris. The 
pellet was discarded and the supernatant was filtrated through 0.45 µm sterile filter (Sarstedt) 
and then applied to a XK16 column packed with 6 mL Glutathione Sepharose Fast Flow (GE 
Healthcare) resin, using affinity chromatography in a fast protein liquid chromatography 
(FPLC) ÄKTATM (Amersham Biosciences). All the process was monitored by Unicorn 
software. 
The column was pre-equilibrated with approximately 5 column volumes of binding 
buffer (1X PBS, pH 7.3) and the sample was injected into the system. The flow rate of 
injection was 0,1-0,2 mL/min. After all the sample being loaded into the column, 5–10 
column volumes of binding buffer was passed through the system (or until no material 
appears in the flow-through). Then, the fusion-protein-bound Glutathione Sepharose medium 
was eluted with Elution buffer (50 mM Tris-HCl, 10 mM Reduced Glutathione (GSH), pH 
8.0). 
Since the protein of interest was eluted with GSH, it was necessary to remove it from 
the samples. Dialysis is the method most used to remove this component.  
A dialysis membrane (Regenerated Cellulose Membrane, Biotech) was cut and 
hydrated in distillated water, and sealed in both ends with clamps as the sample was applied. 
The membrane was immersed in 4000 mL of dyalisis solution (50 mM Tris HCl, 150 mM 
NaCl, 1mM, pH 8.0) O.N. at 4ºC with agitation.   
The fractions were analyzed by SDS-Page and stored at -80ºC. 
Quantification of the protein was done by measuring them with Bradford assay (see 
section III.8), using the dialysis solution as blank.  
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III.7.2. GST-8R-C2 AND GST-TAT-C2 
The purification process was adapted from Frangioni and Neel (1993). 
Frozen pellet was thawed on ice and resuspended in 10 mL of ice cold STE Buffer (10 
mM Tris-HCl, pH 8.0;1 mM Ethylenediamine tetraacetic acid (EDTA);150 mM NaCl). Then, 
5 mM of DTT, 1 mM of PMSF and 1.5 mL of 10% Sarkosyl (final concentration 1,5%) were 
added. All the components were mixed thoroughly by inversion and sonicated for a total time 
of 1 min (On 7’’, Off 10’’ cycle; model 75186, VibraCell). Then 8 mL of 10% Triton X-100 
was added, and the volume was adjusted to a total volume of 20 mL with STE Buffer. At this 
point, the final concentration of Sarkosyl and Triton X-100 was 0.7% and 4%. The solution 
was incubated at RT for 1 h, and then centrifuged at 12000 rpm for 30 min to pellet debris. 
The pellet was discarded and the supernatant was applied to a XK16 column packed with 6 
mL Glutathione Sepharose Fast Flow (GE Healthcare) resin using affinity chromatography in 
a fast protein liquid chromatography (FPLC) ÄKTATM (Amersham Biosciences), and all the 
process was monitored by Unicorn software. 
The column was pre-equilibrated with approximately 5 column volumes of binding 
buffer (1X PBS, pH 7.3) and the sample was injected into the system. The flow rate of 
injection was 0,1-0,2 mL/min. After all the sample being loaded into the column, 5–10 
column volumes of binding buffer was passed through the system (or until no material 
appears in the flow-through). Then, the fusion-protein-bound Glutathione Sepharose medium 
was washed with Cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM 
DTT, pH 7.5) until the values of absorbance and conductivity were stable. 
For each mL of Glutathione Sepharose volume, a mixture of 80 μl of GST-3C Protease 
and 920 μl of Cleavage buffer was prepared and loaded into the column. That process allowed 
to incubate this protease with the recombinant protein at 4ºC O.N., which permitted the 
cleavage of the sample. That way, the eluate will contain the protein of interest, while the 
GST portion of the fusion protein and the GST-3C Protease will remain bound to the 
Glutathione Sepharose medium. 
Following incubation, cleavage buffer was applied to the column to elute all the 
cleaved protein (shown by the absorbance peak at 280 nm), being the eluate collected in 
fractions of 2 mL. 
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After the stabilization of absorbance, the GST-tag and GST-3C bound protein were 
eluted with Elution buffer (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0). 
The eluted fractions were analyzed by SDS-Page and/or Western Blot, and stored at -
80ºC. 
 
 
III.8. PROTEIN QUANTIFICATION: BRADFORD ASSAY 
In order to quantify the purified protein, Bradford method was used, which is based on 
the application of a dye, Coomassie Brilliant Blue G250 (Bio-Rad), at concentration of known 
protein solutions (BSA), allowing the quantification of the unknown samples. 
To prepare protein samples were added to 798 µL MQ H2O, 2 µL of sample and 200 
µL dye. The determination of the samples concentration was performed by reading the 
Abs595nm in a spectrophotometer (Pharmaspec UV-1700, Shimadzu), as well as a straight 
calibration was made in triplicate from standard solutions of known concentrations of BSA 
(0-1500 mg/mL), prepared under the same conditions as the samples. 
 
 
III.9. WESTERN BLOT 
Blotting is a method to transfer proteins or nucleotides (DNA or RNA) onto a 
membrane carrier like nitrocellulose or nylon. Next the proteins or nucleotides are visualized 
by colorant staining (e.g. silver staining of proteins, labelling with chromophoric antibodies or 
radioactive molecules).  
In this thesis, Western Blotting method was used to characterize the product of protein 
purification procedure and to confirm its entrance into the cells after application into them. 
With this method, proteins were separated by SDS-Page on a 12% acrylamide/bis-Acrylamide 
(29:1; NYZTech) gel electrophoresis and then transferred to a nitrocellulose membrane 
(Hybond-C Extra nitrocellulose, Amersham Biosciences) by using an electric current to pull 
the proteins from the SDS-PAGE gel into the membrane. For this to happen, the gel and the 
membrane were previously placed in transfer buffer (192 mM glycine, 20% methanol, 25 mM 
Tris) and subsequently between two pieces of Whatman paper, and two sponges. The 
assembly was inserted into a transfer cassette and the system placed in a container with 
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transfer solution and a cold plate. The electrodes were connected to a power source, and the 
transfer occurred within 60 min, at a fixed amperage of 250 mA and to a maximum of 100 V. 
Afterwards, the nitrocellulose membrane had to be blocked with blocking solution 
(6% dry milk in PBS, 0.2% Tween 20) O.N. at 4ºC to reduce the unspecific reactions in the 
final product of the Western Blot. Then, the membrane was washed with washing solution 
(PBS, 0.2% Tween 20) 3 times for 10 min at RT and under agitation. To stain the transferred 
proteins, the membrane was incubated with a primary antibody - mouse monoclonal JA22 
against CITED2 (ab5155, Abcam) at 1:2000 dilution - specific to the amino acid sequence of 
interest, for 1 hour at RT with agitation.  
After, 3 washes were performed for 10 min with washing solution. Finally, an anti-
mouse secondary antibody coupled to a chromophoric protein (HorseRadish Peroxidase-HRP) 
that binds to the primary antibody for 1 hour at RT with agitation. The washes were repeated 
after incubation. Revelation of the bands was made using SuperSignal® West Pico kit 
(Pierce), accordingly with manufacture’s protocol, and the reaction was detected by image 
acquisition on ChemiDocTM XRS+ Imaging System (BioRad). 
 
 
III.10. CELL ASSAYS 
III.10.1. EMBRIONIC STEM CELL LINES 
To test the functionality of the recombinant protein, we performed several experiments 
with three different cell lines. 
The C2Δ/Δ[MG5] Cited2-null ESC cells, described elsewhere by Kranc et al.(2015), 
were used to study the cellular entrance of the recombinant 8R-CITED2 protein using 
methods like Western Blot and Immunofluorescence. These cells have a deletion of both 
alleles of Cited2 gene and therefore do not express this protein16, making them ideal to detect 
intracellular recombinant protein. These cells are hereafter referred as MG5 cells. 
The C2fl/fl[Cre] cells, described elsewhere by Kranc et al.(2015), were used to study 
the influence of the recombinant protein in the differentiation of ESC cells into 
cardiomyocytes. This mESC line harbour the CITED2 alleles flanked by LoxP sites, and 
constitutively express a tamoxifen-inducible Cre recombinase. 
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E14/T ESC were used for Bifluorescence complementation assays (BiFC). This mESC 
cell line was derived from E14.Tg2a, which was derived by Hooper et al. from 129/OLA in 
198756 and originally developed as a mouse model of Lesch-Nyhan disorder with a deficiency 
of hypoxanthine phosphoribosyltransferase (HPRT). This ESC line grows fast and steadily in 
both feeder and feeder-free systems and is an ideal system for genetic engineering.  
mESC lines were cultured on 0.1% (SIGMA) gelatin-coated plates in GMEM 
(Glasgow MEM, Pan Biotech) medium supplemented with 10% Fetal Bovine Serum (FBS) 
(Sigma), 4 mM L-Glutamin (200 mM GIBCO®, InvitrogenTM), Penicillin/Streptavidine mix 
(GIBCO®, InvitrogenTM), 1X Non-essential aminoacids (GIBCO®, InvitrogenTM), 0.05 mM β-
mercaptoethanol (GIBCO®, InvitrogenTM) and 1 mM Sodium Pyruvate (GIBCO®, 
InvitrogenTM). Additionally 1000 U/mL of Leukemia Inhibitory Factor (LIF) (ESGRO mLIF 
Meddium Supplement, Millipore) was added to the medium, since it is an interleukin 
6 class cytokine that affects cell growth by inhibiting differentiation.  
Cultures were maintained in culture at 37ºC with 5% CO2.The cultures were 
monitored under inverted microscope. 
 
 
III.10.2. CELLULAR ENTRANCE OF RECOMBINANT PROTEIN 
5x104 MG5 cells were seeded in a 24 well plate, previously prepared with 0.1% 
gelatin and incubated at 37ºC, 5% CO2, O.N. 
Protein solutions were thawed and diluted with the culture medium and stored at 4ºC 
prior to supplementation of cell cultures.  
Next day, the medium in contact with the cells was replaced by the medium where the 
protein had been dissolved at the desired concentration (20 µg/mL). 
At different time points (4 h, 8 h, 12 h and 24 h), cells were recovered, by washing 
them with PBS 1X, adding 80 µL of trypsin (a proteolytic enzyme which breaks down 
proteins) to dissociate adherent cells from the plate. Since long exposure to trypsin can affect 
the cells, when the cells appeared to be detached, 160 µL of medium with serum was added to 
deactivate the enzyme. The mixture was then transferred to a 1.5 mL centrifuge tube and 
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centrifuged at 15000 rpm for 1 min, being the supernatant discarded and the pellet stored at -
80ºC. 
Protein lysates were prepared in cold lysis buffer (Tris 50 mM (pH7.5), 180 mM 
NaCl, 0.5% NP-40) supplemented with complete protease inhibitors 25X (Roche), 1 mM 
DTT, 0.2 µM Sodium Ortho-Vanadate (Na3VO4, Sigma) and 100 µM PMSF 
(PhenylMethylSulfonyl Fluoride, Sigma). Final protein concentrations were measured using 
Bradford protein assay as previously described. 
Approximately 30 µg of protein lysates were applied to a SDS-Page gel and the 
process of Western Blotting was done as previously described (see section III.7). 
 
 
III.10.3. FLUORESCENCE IMMUNOCYTOCHEMISTRY 
In order to detect if 8R-CITED2 would enter the cells and the nuclei, a fluorescence 
immunocytochemistry assay was performed in complementation with a Western Blot. 
This technique is composed by 6 steps: coverslip preparation, fixation of cells, 
permeabilization of cells, blocking, antibody incubation and DAPI staining. 
First, is necessary to prepare the cells to the visualization in slides, so the cells needed 
to be placed into coverslips. These coverslips required to be prepared in order to the cells 
adhere (the cells don’t adhere to glass), so they were washed with 70% ethanol in a 50 mL 
conical tube, followed by a wash with PBS 1X. Using clean forceps, coverslips were hold 
vertically to dry and placed inside a well in a 6-well plate. To each of them, 200 µL of 0.1% 
gelatin covered the surface of the coverslip for 10 min and then removed. MG5 cells were 
plated into the coverslips (5x104 cells/coverslip) in a total volume of 300 µL of medium per 
coverslip. 8R-CITED2 was added to medium with the cells at 20 µg/mL concentration, and let 
incubate at 37ºC O.N. 
The day after, we proceeded to fixation of cells. For that, the media from the 
coverslips was removed and the cells were washed with 1 mL PBS. PBS was removed and 1 
mL of 2% paraformaldehyde (Sigma) diluted in PBS was added and incubated for 20 min at 
RT. 
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To allow the antibodies to enter the cells, it was necessary to make them permeable. 
For that, the fixation solution was removed, and 1 mL of Permeabilization solution (0.1% 
(v/v) Triton X-100 (Sigma)) was added and incubated for 20min at RT. Then, 
permeabilization solution was removed and 1 mL of Washing solution (.,02% Tween in PBS) 
was added for 5 min to wash the cells. The washing solution was then removed and the 
blocking step was performed. 
To each coverslip, 1 mL of Blocking solution, containing 100 mM glycine (Merck), 2 
mg/mL Bovine Serum Albumin (BSA; NZYTech) and 0.02% sodium azide (Sigma) in PBS, 
was added and incubated at least for 30 min and keep at 4ºC until use. 
The following step was antibody incubation. First, 150 µL of the primary antibody - 
rabbit polyclonal anti-CITED2 (H-220, Santa Cruz Biotechnology) - was added at 1:100 
dilution in blocking solution, for 2 h at RT. Next, coverslips were washed three times in 
0.02% Tween (Sigma) diluted in PBS for 5 min and incubated with 150 µL of secondary 
antibody - AlexaFluor-488 donkey anti-rabbit antibody (Invitrogen) - at 1:2000 dilution in 
blocking solution for 1 h at RT. The coverslips were then washed three times with washing 
solution for 5 min. 
To make the nuclei visible, it was needed to stain it with DAPI. A volume of 500 µL 
of DAPI at 1 µg/mL diluted in PBS was used for coverslip and incubated for 5 min. Then, the 
coverslips were washed with washing solution for 5 min, and placed onto slides using 
Fluoromount (Sigma).  
Fluorescence microscopy was performed using an Axioimager Z2 microscope (Carl 
Zeiss) at 100X magnification. Negative controls were used to set up exposure conditions for 
detection of a specific signal. 
Treatment of resulting images was done using software ImageJ, respecting the same 
parameters in control cells and recombinant protein treated cells. 
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III.10.4.  BIMOLECULAR FLUORESCENCE COMPLEMENTATION (BIFC) 
Protein interactions are a fundamental mechanism and can be studied by different 
methods which make the protein-protein interactions visible, not only revealing the 
interactions, but also show where those interactions take place. This is of great importance to 
study the interactions among transcription factors.57 
BIFC analysis is one of the methods which enables direct visualization of protein 
interactions in living cells. The principle is based on the formation of a fluorescent complex, 
when two non-fluorescent fragments of a fluorescent protein (like YFP), interact to each 
other. The interaction between the fusion proteins facilitates the association between the 
fragments of the fluorescent protein making the fluorescence appear. 23 
The vectors used in this assay were described previously by the group58, using 
pPyCAGIP vector modified and obtaining the following vectors: 
- VEC-CITED2, which is a vector expressing the C-terminal fragment (residues 
156-239) of Venus-YFP fused in frame to a flag-tagged CITED2 at its N-terminal 
region. 
- VEN-CH1, which is a vector expressing the N-terminal fragment (residues 1-155) 
of Venus-YFP fused in frame to the CH1 domain of p300 (high affinity domain of 
interaction with CITED2). 
Fluorescence detection of transfected cells will be originated by the close proximity of 
the residues 1-155 and residues 156-239 of Venus-YFP. 
First, cells had to be prepared the day before transduction, so we plated 5x104 of E14/T 
ESC for well in a 24-well plate, and let the cells incubate at 37ºC, 5% CO2 for 24 h. At the 
same time, protein solutions were thawed and diluted with the culture medium 24 h and stored 
at 4ºC prior to supplementation of cell cultures.  
Next day, the transfection solution was prepared to each well. 25 ng of DNA of each 
of the vectors was diluted in medium and the solution of Lipofectamin 2000 (Invitrogen) was 
carefully added to the DNA mix, drop by drop. Before application of the transfection solution, 
the cells were washed with medium and finally the solution was applied to the wells. After 4 
h, 2 mL of fresh complete medium were added to each well. 
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After 24 h, the medium was changed and at that time we added 8R-CITED2 at 20 
µg/mL and 40 µg/mL concentration. 
After days, pictures were taken at 10X in a confocal microscope, and cells were 
counted using ImageJ software. 
 
 
III.10.5. CARDIAC DIFFERENTIATION - HANGING DROP METHOD  
To induce ESC differentiation, hanging drop method was the chosen one. To this 
experiment, GMEM was prepared with supplements as referred before, but without the 
addition of LIF (since this factor maintains pluripotency of the cells and we wanted them to 
differentiate), and raising the concentration of FBS to 20%. 
C2fl/fl[Cre] cells were prepared in a cell suspension containing a defined cell number 
(5 x 104 cells/plate) and placed in a 100 mm bacteriological petri dish in 20 µL volume drops 
(Day 0). Then plates were inverted (upside down), and 1 mL of PBS was added to the bottom 
part of the plate to maintain the humidity inside them. Plates were cultivated in hanging drops 
at 37ºC with 5% CO2 for 2 days. The cells aggregated and form one EB per drop.  
At day 2, EBs were formed, and PBS was removed. Plates were then inverted and 4 
mL of GMEM medium was added. After 3 days, EBs were transferred onto 60 mm tissue 
culture dishes, previously coated with gelatin. 
The first beating cardiomyocytes appear in two to three days after plating of 5 days old 
EBs. 
 
To study the influence in cardiomyocyte differentiation by the produced recombinant 
proteins, we had to compare them with different conditions to the controls.  
At day 2 of differentiation, the plates were inverted and 8R-Cited2 was added to the 
medium in concentrations of 5-10 µg/mL where C2fl/fl[Cre]  had suffered a knock-down by 
the addition of 1 µM 4-hydroxytamoxifen (4HT). As controls we used C2fl/fl[Cre] with 
ethanol (4HT is diluted in ethanol), and C2fl/fl[Cre] with 4HT. 
We observed the differentiation of cells in culture by light microscopy, since it is a 
simple and efficient way to assess the morphological changes of the cells and to observe the 
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emergence of beating foci. Percentage of colonies with beating foci and average number of 
beating foci per colonies with beating foci were counted 8 to 10 days after the initiation of 
differentiation. 
 
 
III.11. STATISTICAL ANALYSIS   
The Two-way analysis of variance (ANOVA) with the multiple comparison test 
(Tukey test) were performed to compare groups. All analyses were run using the GraphPad 
Prism (version 6.1) software. 
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IV. RESULTS AND DISCUSSION 
 
IV.1. CONSTRUCTION OF EXPRESSION VECTORS  
The empty pGEX-6P-1 vector was digested by the endonuclease BamHI to linearize 
the vector. After dephosphorilation with CIP to avoid self-closure of the vector during the 
ligation process, a TAE agarose gel was performed for further purification of the band.  
 
 
 
Figure IV.1 - Visualization of pGEX-6P-1 digestion product by BamHI in a 1% agarose gel. 
Gel was stained with GreenSafe. Lane L corresponds to the ladder GeneRuler DNA Ladder Mix 
(Thermo Scientific). Lane 1 shows the pGEX-6P-1 digestion product. 
 
The linearized vector has an expected length of 4984 bp, therefore the band visualized 
on agarose gel electrophoresis which migrates close to 5000 bp indicates a correct digestion 
of the plasmid (Figure IV.1). 
This band was then cut off the gel, purified with GeneJETTM Gel Extraction Kit and 
the DNA resulting from the extraction was quantified using a Nanodrop 2000. 
Next, we inserted at the BamHI site of the pGEX-6P-1 vector, double stranded 
oligonucleotides encoding either the TAT or 8R peptides. As mentioned in methods section, 
these oligonucleotides were designed to place TAT or 8R in frame with the GST protein 
expressed by pGEX-6P-1.  
The ligation between the inserts and the linearized vector was performed and the 
products of the ligation were transformed into DH5α cells, which were plated and incubated 
overnight at 37°C. A negative control (a digested and dephosphorylated plasmid without the 
insert) was performed at the same time to estimate the background of the transformation due 
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to an auto-ligation of the empty vector. No colonies were observed in the control plate (the 
linearization and dephosphorilation steps were successful), while four single colonies were 
present in pGEX+TAT transformed cells plate. The positive colonies were amplified in liquid 
medium and the plasmid DNA of these colonies was purified and subjected to a diagnostic 
digestion with SacII and PstI. 
Restriction enzymes for the diagnostic digest were chosen based in their possible 
restriction sites in the vector or insert. PstI only has a unique restriction site in the host vector 
(position 1937bp), which would linearize the vector. Meanwhile, the SacII enzyme only has a 
unique restriction site localized in the insert. Thus, a double digestion of the expected 
construct, in other words, with the TAT inserted in the correct orientation, would generate 
two DNA fragments of 996 bp and 4033 bp. The insertion of the TAT expressing 
oligonucleotides in the wrong orientation would give rise to two fragments of 1027 bp and 
4002 bp, while the absence of insert would give rise to a unique fragment with a size of 4984 
bp. 
After digestion by PstI and SacII of the four clones, the resulting fragments were 
separated and visualized in an agarose gel (Figure IV.2). 
 
 
 
Figure IV.2 - Visualization of the plasmid DNA isolated from positive colonies to pGEX-6P-
1+TAT, digested with SacII and PstI in a 1% agarose gel. Gel was stained with GreenSafe. Lane 
L corresponds to the ladder GeneRuler DNA Ladder Mix (Thermo Scientific).  Lane 1 to 4 shows 
double digestion of 4 possible successful clones of pGEX-6P-1+TAT. 
 
As we can observe three of the four clones, 1, 3 and 4, present two bands at 
approximately 1000 bp and 4000 bp (theoretically corresponding to bands of 996 bp and 4033 
bp) suggesting they underwent an appropriate ligation. Clone number 2 showed two bands 
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(Figure IV.2), approximately at the same sizes, but the band at 1000 bp is slightly above the 
others, which suggested that the insert is inverted (theoretically corresponding to bands of 
1027 bp and 4002 bp).  
For further experiments, we selected the clone number 4 because the concentration of 
plasmid DNA was higher than the others (42 ng/μl). 
For the pGEX+8R construction (Figure IV.3), no colonies were observed in the 
control plate and two single colonies were present in the plate of cells transformed with the 
ligation products resulting from the ligation of the plasmid and the insert. The plasmid DNA 
of the 2 positive clones was amplified, purified and subjected to a diagnostic digestion with 
BamHI and PstI. A correct insertion of the oligonucleotides encoding the 8R in the vector 
should give rise to two bands of 996 bp and 4033 bp after a double digestion by BamHI and 
PstI.  
As we can observe only one (clone 1) of the two colonies had an appropriate plasmid 
DNA digestion profile on an agarose gel (Figure IV.3). Clone number 1 was selected and 
clone number 2 was discarded, since it showed only one band, which means that pGEX-6P-1 
entered the cells allowing them to grow as a colony (due to a working Amp resistance gene) 
but didn’t incorporate the insert. 
 
 
Figure IV.3 – Visualization of the plasmid DNA isolated from positive colonies to pGEX-6P-
1+8R, digested with SacII and PstI in a 1% agarose gel. Gel was stained with GreenSafe. Lane L 
corresponds to the ladder GeneRuler DNA Ladder Mix (Thermo Scientific). Lane 1 and 2 show 
double digestion of the possible successful clones of pGEX-6P-1+8R. 
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Next, we needed to isolate the CITED2 DNA sequence from an existing expression 
vector (pSB5431) and insert it into the two previous prepared vectors: pGEX-6P-1+TAT 
(referred hereafter as pGEXT) and pGEX-6P-1+8R (referred hereafter as pGEXR).  
The CITED2 insert was excised from pSB54, using the BamHI and XhoI restriction 
enzymes. The same enzymes were used to digest the pGEXT and pGEXR vectors in order to 
perform the cloning. Importantly, the insertion of the CITED2 fragment excised by BamHI 
and XhoI in these vectors will locate the CITED2 cDNA in frame with the GST and the TAT 
or 8R peptide sequences.  
To control the restricted endonuclease reaction and to select the cut out 
polynucleotides a TAE agarose gel was performed. 
 
 
The length of the vector pSB54 is 6391 bp and the double digestion by BamHI and 
XhoI is expected to originate two fragments: one of the fragments with a length of 923 bp 
corresponds to the CITED2 fragment and the other fragment with a length of 5468 bp results 
from the remaining plasmid DNA. 
The digestion of pGEXT and pGEXR vectors by BamHI and XhoI should originate a 
5005 bp fragment corresponding to the linearized vectors and a fragment of 24 bp long, which 
will not be detected on a conventional agarose gel. 
A 
 
B 
 
Figure IV.4 – Visualization of pSB54, pGEXT and pGEXR double digested with BamHI and 
XhoI, in a 1% agarose gel in order to isolate and purify inserts and vectors. Gels were stained 
with GreenSafe. Gel A corresponds to the double digestion of pSB54 (lane 1) and pGEXT (lane 2). 
Gel B corresponds to the double digested pGEXR (lane 1). Lane L corresponds to the ladder 
GeneRuler DNA Ladder Mix (Thermo Scientific) and red rectangles correspond to the fragments 
excised to further purification of the DNA.  
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On an agarose gel, we separated the fragments resulting from the digestion of pSB54 
vector, and determined that a fragment corresponding to the vector itself (above 5000 bp) was 
present with the fragment corresponding to CITED2 DNA, which had about 1000 bp, 
according to the ladder on the gel (lane 1 from Figure IV.4.A).  In lane 2 (pGEXT), the 
expected fragment had the right length (around 5000 bp) while the cut out DNA fragment of 
24 bp is not visible. The same happened with in pGEXR (lane 1 from Figure IV.4.B).  
The relevant DNA fragments were excised from the gel and purified as referred in 
section III.1.3. 
After that, we needed to insert the CITED2 DNA fragment into pGEXT and pGEXR 
vectors by ligation (for 2 h and 4 h). The ligation products were transformed into DH5α cells, 
which were plated and incubated O.N. at 37°C. The negative control (plasmid without the 
insert) transformed cells was also obtained at the same time to verify if the vector would self-
close.  
 
Three single colonies arose in pGEXT-CITED2, which suffered ligation reaction for 2 
hours, and two colonies from DH5α transformed with DNA ligated for 4 hours. All colonies 
were picked from transformed cells plate, amplified and the plasmid DNA was purified and 
used for a diagnostic test digestion with BamHI and XhoI. 
A 
 
B 
 
 
Figure IV.5 - Double digestion with BamHI and XhoI of pGEXTC2 (A) and pGEXRC2 (B) in 
a 1% agarose gel in 1X TAE, stained with GreenSafe, to confirm the insertion of CITED2 
gene. (A) Lanes 1 to 3 correspond to DNA isolated from colonies transformed with plasmid DNA 
ligated for 2 h. Lanes 4 and 5 correspond to DNA isolated from colonies transformed with plasmid 
DNA ligated for 4 h. (B) Lanes 1 and 2 correspond to DNA isolated from colonies transformed with 
plasmid DNA ligated for 4 h. Lane L corresponds to the ladder GeneRuler DNA Ladder Mix 
(Thermo Scientific). 
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In the case of pGEXR-CITED2, the ligation reaction was done for 4 h since it seemed 
to increase the efficiency of the reaction. After transformation of DH5α, plasmid DNA from 
two colonies was extracted to perform the same test diagnostic digestion. The expected bands 
were 1000 bp corresponding to Cited2, and 5000 bp corresponding to the vector itself 
(pGEXT or pGEXR). 
Observing the results (Figure IV.5), we can conclude that neither of the 3 clones 
ligated for 2 h (lane 1 to 3) was a successful one, since none of them present the expected 
bands, showing only one band at 5000 bp, and therefore not having the insert. 
Opposing to these results, the DNA fragments (pGEXT and CITED2) which suffered 
the ligation reaction for a longer time (4 h), presented a band at 1000 bp in both of the picked 
colonies. This band corresponds to the insert CITED2 which was successfully cloned into 
pGEXT. 
In the gel corresponding to the diagnostic digest from pGEXR-CITED2 colonies, we 
can distinguish two good defined bands at 1000 bp and 5000 bp, which confirmed the 
presence of the insert. After this selection, cloned plasmid DNA was sent to sequencing.  
 
 
IV.2. RECOMBINANT PROTEIN PRODUCTION 
For expression of recombinant proteins, a suitable production system had to be 
established. Initially we faced some problems, such as the poor solubilization of the 
bacterially expressed protein, forcing its accumulation in inclusion bodies, which leads to a 
low yield in the production of the protein. 
 Many expression screenings were performed to overcome the problems and optimize 
the expression, like modifying the starting point of the induction, varying IPTG 
concentrations, duration of induction and temperature of expression. 
 
IV.2.1. PRODUCTION AND PURIFICATION OF 3C PROTEASE 
The 3C protease protein was produced as described in the methodology section, using 
BL21 (DE3) cells. Samples were collected before and after induction by IPTG to be analyzed 
Results and Discussion 
45 
by SDS-Page to confirm the expression of the protein of interest after total protein stain 
(Figure IV.6). 
 
  
Figure IV.6 - SDS gel stained with Coomassie Blue to verify the expression of the recombinant 
protein: GST-3C. 1 represents the protein extract from cell lysate before IPTG induction and 2 
represents the protein extract from cell lysate after IPTG induction. L corresponds to the ladder 
used: PageRulerTM Prestained Protein Ladder (Fermentas Life Sciences). 
  
 
The expression of a protein of 46 kDa was stimulated in the bacteria transformed with 
the GST-3C protease expression vector and treated with IPTG (Figure IV.6, lane 2), 
suggesting that GST-3C protease is expressed in our extracts.  
We further proceeded to the purification of the protein of interest (GST-3C) from the 
other proteins produced by BL21 (DE3). To separate these components, we resorted to 
chromatographic affinity methods, which are based on the specific interaction of the sample 
with a substrate (GST) in stationary phase (chromatographic column). 
The frozen cells transformed with the GST-3C expression vector and treated with 
IPTG were resuspended in PBS and disrupted by sonication. After the separation of the 
supernatant and the cell lysates, the supernatant was applied to a XK16 column packed with 
Glutathione Sepharose Fast Flow resin to perform an affinity chromatography in a FPLC 
ÄKTATM. The basis of this method is the interaction of GST fusion protein with the resin of 
the GSTrap column.  
All the process was monitored by Unicorn software. This software allowed to register 
the alterations in several conditions like Abs 280nm and % of Elution Buffer injected into the 
column, and this way we could obtain a chromatogram of the process. 
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Figure IV.7 – Purification chromatogram of the recombinant protein GST-3C. 10 mL of soluble 
extraction was injected into a XK 16/20 column packed with Glutathione Sepharose 4 Fast Flow, and 
isolated by affinity chromatography to GST-GSH. Elution was performed with 10 mM of GSH. 
 
Based on Figure IV.7, it is possible to evaluate the stages of the chromatographic 
purification process of GST-3C protein. The Abs280nm is an indicator of the presence of protein 
in the collected solution.  
At the start of the chromatographic process, where the sample is injected into the 
column, we can observe a remarkable increase in absorbance corresponding to the 
proteinaceous material that was not adsorbed. 
At this step, GST fused proteins were retained, due to their affinity to the Glutathione 
(GSH) coupled to the resin, while the remaining was entrained in the mobile phase.  
After selective immobilization and the collection of flow-through, the absorbance 
stabilized. Then, the protein of interest could be eluted from the column when in the presence 
of a solution of reduced GSH, a competitive molecule. The addition of this Elution Buffer to 
the column can be observed by the dotted yellow line in the chromatogram, and should be 
gradual in order to try to obtain the protein with higher grade of purity. The protein sample 
output increases the absorbance and at this point, the purified protein was collected in 7 
fractions of 2 mL. 
Samples from the injected solution, flow-through and the fractions of interest were 
analyzed by SDS-Page. 
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Figure IV.8 – SDS-Page analysis of sample purification steps stained with Coomassie Blue. 
Lane 1 corresponds to the soluble fraction/injected sample, lane 2 shows the flow-through and lanes 
3 to 9 shows the eluted fractions of GST-3C. L corresponds to the ladder used: Precision Plus 
Protein™ Unstained Standard (Bio Rad). 
 
The analysis of the SDS-Page gel (Figure IV.8), indicates that the injected sample, 
corresponding to the mix of all the soluble proteins produced by the transformed BL21 (DE3), 
has a ticker band which corresponds to the protein of interest. In flow-through fraction, it is 
possible to see that our protein is still present.  
The eluted fractions had sharp and well defined bands migrating between the 50 kDa 
and 37 kDa bands of molecular weight markers, corresponding to our protein of interest 
which has 46 kDa. 
No other bands were visible in the eluted fractions, meaning that the purification 
process was efficient, and allowed the preparation of GST-3C with a high grade of purity. 
 
 
IV.2.2. PRODUCTION AND PURIFICATION OF GST-TAT-CITED2 AND 
GST-8R-CITED2 PROTEIN 
These recombinant proteins were produced as described in the methodology section, 
using BL21 (DE3) cells.  
Samples were collected before and after induction by IPTG to be analyzed by SDS-
Page to confirm the expression of the protein of interest (Figure IV.9). 
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The analysis of the SDS-PAGE results indicates an increase in the production of GST-
TAT-CITED2 and GST-8R-CITED2 after the induction by IPTG (Figure IV.9). GST-TAT-
CITED2 has a predicted molecular mass of 57 kDa and examining the presented gel, we can 
confirm that the band induced by IPTG has the expected molecular weight. Analyzing the gel 
representing the production of GST-8R-CITED2, we can also observe a band with the 
expected molecular weight which is approximately 56 kDa. 
Next, we proceeded to the purification of these proteins of interest using an approach 
similar to the one used for the purification of GST-3C, employing chromatographic methods. 
In both cases, frozen bacterial pellets were thawed on ice and resuspended in ice cold 
STE Buffer with DTT, PMSF and Sarkosyl, and disrupted by sonication on ice. Triton X-100 
was added to lysate, and the mixture was left to incubate, before performing a centrifugation 
in order to separate the supernatant and the cell debris. The soluble fractions were applied to 
the XK16 column packed with Glutathione Sepharose Fast Flow resin using affinity 
chromatography in a FPLC ÄKTATM. The basis of this method was described before for 
GST-3C protease purification.  
All the process was monitored by Unicorn software to obtain a chromatogram of the 
process. Unfortunately, the chromatogram of the purification of TAT-CITED2 could not be 
obtained since the software failed to save the data, however that chromatogram was 
A 
 
B 
  
Figure IV.9 – SDS-Page gels stained with Coomassie Blue to verify the expression of the 
recombinant proteins (A) GST-TAT-CITED2 and (B) GST-8R-CITED2. 1 represents the 
protein extract from cell lysate before IPTG induction and 2 represents the protein extract from cell 
lysate after IPTG induction. L corresponds to the ladder used: PageRulerTM Prestained Protein 
Ladder (Fermentas Life Sciences). 
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essentially similar to the chromatogram obtained during the purification of 8R-CITED2 
(Figure IV.10). 
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Figure IV.10 - Purification chromatogram of the recombinant protein 8R-CITED2 with on-
column cleavage. 20 mL of soluble extraction was injected into a XK 16/20 column packed with 
Glutathione Sepharose 4 Fast Flow, isolated by affinity chromatography to GST-GSH, and cleaved 
O.N. at 4ºC with GST-3C protease. 8R-CITED2 (first peak after cleavage) was then released from 
the column and recovered in fractions. Further elution of GST-tag and GST-3C was performed with 
the application of 10 mM of reduced GSH. 
 
The samples were injected into the column (20 mL), and the GST fused proteins were 
retained, due to their affinity for the resin, while the remaining proteins exited the system 
(flow-through sample was collected). After this selective immobilization the absorbance 
stabilized.  
At this point, we injected the GST-3C protease to the column to cleave the GST tag 
from the protein of interest TAT-CITED2 or 8R-CITED2. We performed this on-column. On-
column cleavage (see Figure IV.11) is generally recommended as the method of choice since 
many potential contaminants can be washed out and the target protein eluted with a higher 
level of purity.  
 
Results and Discussion 
50 
 
 
Figure IV.11 - Flow chart of the affinity purification procedure and GST-3C Protease 
cleavage of GST fusion proteins.  
 
Before addition of GST-3C protease, the GST-fusion protein of interest was 
equilibrated in the protease cleavage buffer. For this purpose, we washed the column with 10 
column volumes of GST-3C cleavage buffer before loading the GST-3C protease mix onto 
the column and sealing both ends of the column. We let the protein of interest in contact with 
the protease O.N. at 4º C.  
Then, the protein of interest (TAT-CITED2 or 8R-CITED2) was eluted from the 
column when the flow was restored and the eluates were collected in fractions of 2 mL. The 
elution was monitored in the chromatogram of the absorbance levels. To remove the GST 
moiety of the fusion protein and the GST-3C protease, we applied a competitive solution 
containing reduced GSH molecules. The addition of this Elution Buffer to the column can be 
observed by the dotted yellow line in the chromatogram (Figure IV.10). The output of these 
molecules can be observed again in the chromatogram by the increase in the absorbance. 
Samples from the injected solution, flow-through and the fractions of interest were 
analyzed by SDS-PAGE (Figure IV.12 and IV.13) and Western Blotting (Figure IV.14).  
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The SDS-PAGE gel from the purification of TAT-CITED2 revealed that this protein 
was partially lost in the insoluble fraction since the band is also strong in that fraction (Figure 
IV.12). Following the purification process, we can verify that the protein was successfully 
bond to the GST beads, since in the lane 3 the protein is significantly less detected. After 
digestion with GST-3C protease, protein was collected in 2 mL fractions (lane 4-8) and the 
band observed is around 32 kDa, which is what we expected (57 kDa recombinant protein – 
25 kDa GST tag = 32 kDa). In the last lane we can observe the eluted GST-tag and the GST-
3C protease (46 kDa). 
 
 
Figure IV.12 - SDS-PAGE gel stained with Coomassie Blue to monitor the purification 
process of TAT-CITED2. Lane 1 represents the insoluble fraction of protein extract, lane 2 
represents the soluble fraction which was injected into the column and lane 3 corresponds to flow-
through from the column. Purified protein can be observed in lane 4 to 8, while the GST tag and 
GST-3C protease are represented in lane 9.  L corresponds to the ladder used: Precision Plus 
Protein™ Unstained Standard (Bio Rad). 
A 
 
B 
 
Figure IV.13 – SDS-Page gel stained with Coomassie Blue to monitor the purification process of 
8R-CITED2. Lane 1 represents the insoluble fraction of protein extract, lane 2 represents the soluble 
fraction which was injected into the column and lane 3 corresponds to flow-through from the column. 
Lanes 4 and 5 represent the washings steps performed before the application of GST-3C protease. 
Purified protein can be observed in lane 6 to 12, while the GST tag and GST-3C protease are 
represented in lanes 13 to 16.  L corresponds to the ladder used: PageRulerTM Prestained Protein 
Ladder (Fermentas Life Sciences). 
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The 8R-CITED2 purification was also relatively successful. Indeed, in the SDS-PAGE 
(Figure IV.13), we distinguish a stronger band in lanes 1 and 2, slightly above the 55 kDa, 
which corresponds to the molecular weight of the protein of interest. However, like TAT-
CITED2, a fraction of the 8R-CITED2 protein was lost in the process of separation of soluble 
and insoluble fractions in protein extraction.  
The recombinant protein was successfully isolated from the remaining proteins as we 
can see in the lanes 3 to 5, since there was a substantial decrease in the intensity of the interest 
band. After the digestion step, 2 mL fractions were collected (lane 6-12), and the band 
obtained was located between 25 and 35 kDa, corresponding the expected molecular weight 
(56 kDa recombinant protein – 25 kDa GST tag = 31 kDa). The protein was not completely 
purified as indicated by the presence of other bands in lanes 6 and 7. These fractions were not 
used in further studies. 
In the last lanes (13-16) we observed the eluted GST-tag and the GST-3C protease (46 
kDa). 
 
After the isolation and purification of the recombinant proteins TAT-CITED2 and 8R-
CITED2, we confirmed their identity by Western Blotting using a specific antibody against 
CITED2. 
Purified proteins were quantified using the Bradford method and 3 µg of protein 
extracts were loaded and separated on SDS-PAGE gel. After the transfer of the proteins to a 
nitrocellulose membrane and blockage of this membrane with milk proteins, the mouse 
monoclonal JA22 antibody against CITED2 (ab5155, Abcam) was used as primary antibody 
at 1:2000 dilution, followed by the incubation with anti-mouse HRP. 
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A 
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Figure IV.14 – Western Blots to confirm the identity of the purified proteins: (A) TAT-
CITED2 and (B) 8R-CITED2. 1 represents the analysed protein and L corresponds to the ladder 
used: PageRulerTM Prestained Protein Ladder (Fermentas Life Sciences). 
Analyzing the Western Blots results in Figure IV.14, we observed three or more 
bands. A band with a lowest migrating ability located between 25 and 35 kDa corresponds to 
the expected size of the 8R-CITED2 and TAT-CITED2 protein. The lower molecular weight 
bands, in both cases, suggest that the purified protein suffered a degradation of some sort, 
which could be caused from poor handling of the samples prior to analysis, like shifts in the 
temperature. When the purification procedure was done, a sample of the fractions was kept at 
-20ºC while the fractions themselves were stored at -80ºC to avoid degradation. To run the gel 
we used the samples kept at -20ºC, which could explain the degradation presented in the 
Western Blots. 
 
 
IV.3. CELLULAR ENTRANCE OF RECOMBINANT PROTEIN 
To analyze the stability and test the ability of 8R-CITED2 protein to enter cells in 
culture, we supplemented MG5 mESC in culture with 20 µg/mL 8R-CITED2 or the 
equivalent volume of elution buffer (used as control). MG5 were used because they lack of 
the expression of endogeneous Cited2.16 Therefore, if any signal was detected inside the cells 
by anti-CITED2 after 8R-CITED2 supplementation, it would indicate that the recombinant 
protein penetrated the cell membranes to enter the cells. MG5 cells were harvested after 4, 8, 
12 and 24 h after supplementation of recombinant purified 8R-CITED2. 
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The presence of 8R-CITED2 inside MG5 mESC was analyzed in whole cell extracts 
by Western Blotting as described above (Figure IV.15) and further confirmed by 
immunostaining analysis (Figure IV.16). 
 
 
Figure IV.15 – Western Blot to evaluate the penetration of the recombinant protein 8R-
CITED2. Cellular uptake of the recombinant protein was detectable in cell lysates of 12 h and 24 h. 
L corresponds to the ladder used: PageRuler™ Prestained Protein Ladder (Fermentas Life 
Sciences). 
 
Temporal analysis showed that the 8R-CITED2 protein was detectable in cells only 
after 12 h of being added to the culture media. The detection was stronger in the extracts 
harvested at 24 h.  
However, extra several bands with higher molecular sizes were detected, suggesting 
that the recombinant 8R-CITED2 protein has the tendency to form aggregates in the cell, like 
we observed in vitro during the purification, or the protein undergoes some modifications, 
such as phosphorylation or ubiquitination, as it has been reported.58,59 These aggregates 
formation may impair the optimal capacity of the recombinant 8R-CITED2 to translocate into 
the cells. 
 
 
IV.4. FLUORESCENCE IMMUNOCYTOCHEMISTRY  
Cellular entrance of recombinant 8R-CITED2 was further confirmed by 
immunostaining analysis of MG5 cells in culture treated with 20 µg/mL 8R-CITED2 protein 
or elution buffer as control O.N. at 37ºC, since the protein would need at least 12 h to enter 
the cells (as indicated by the results obtained in the Western Blot).  
Before fixation, cells were carefully washed to ensure the removal of all 8R-CITED2 
proteins that were loosely bound to the cell surfaces. Then, cells were permeabilized, blocked 
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with BSA and finally incubated with anti-CITED2 antibody as a primary, and AlexaFluor-488 
antibody as secondary antibody. The nuclei were stained with DAPI. 
As expected no or a residual fluorescence was detected in the control, since MG5 cells 
lack Cited2 expression, while a fluorescent signal was detected in the cells transduced with 
the recombinant protein (Figure IV.16) . 
Overall, these experiments indicated that 8R-CITED2 enters mESC and translocate 
into the nucleus. However, the conditions need to be optimized to avoid the formation of 8R-
CITED2 aggregates which might decrease the active fraction of 8R-proteins in the cells. 
 
 
IV.5. COMPETITION ESSAY BETWEEN 8R-CITED2 AND ENDOGENOUS 
CITED2 FOR P300 INTERACTION 
CITED2 has a very high affinity for the CH1 domain of p300.31,33 We have previously 
set an ex vivo assay to monitor CITED2-CH1 interaction based on BIFC. For this assay, cells 
 
 
Figure IV.16 – Fluorescence microscopy of MG5 cells treated with 20 µg/mL of 8R-CITED2 
detected by immunocytochemical reaction against CITED2, 24 h after supplementation, at 
100X magnification. Negative controls were used to set up exposure conditions for detection of a 
specific signal. 
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are transfected with vectors expressing either the CH1 domain of p300 fused to the N-
terminal domain of the VENUS fluorescent protein (VEN-CH1) or CITED2 fused to the C-
terminal domain of VENUS (VEC-CITED2), as described previously.58 The interaction 
between CITED2 and the CH1 domain will bring the VENUS domains in close proximity, 
which will allow the emission of fluorescence. To test the functionality of 8R-CITED2 inside 
the cells, we evaluated the capacity of 8R-CITED2 protein to interfere/disrupt the endogenous 
interaction between VEC-CITED2 and the VEN-CH1 domain. 
 The 8R-CITED2 was added to the culture media of E14/T ESC, at two different 
concentrations (20 and 40 µg/mL), expressing VEC-CITED2 for VEN-CH1 and the detection 
of fluorescence in these conditions was compared to the control cells (E14/T with no 
recombinant protein) (Figure IV.17). The supplementation of 8R-CITED2 recombinant 
protein led to a decrease of the fluorescence detected in a dose-dependent manner, indicating 
that 8R-CITED2 competes with VEC-CITED2 for the interaction with VEN-CH1. 
 
A
 
 
B 
 
 
 
 
Figure IV.17 – Representative fields of E14/T ESC co-transfected cells with plasmids expressing 
VEN-CH1 and VEC-CITED2 and quantification of the fluorescence detected with different 
concentrations of 8R-CITED2. The detection of fluorescence was visualized 48 h after transfection 
(A). The number of fluorescent cells is presented relative to the fluorescence detected in the control 
condition (VEN-CH1/VEC-CITED2) set to 1. All values are represented as Mean±SEM (n=5) 
followed by a Two-way ANOVA treatment (B). 
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The number of cells emitting fluorescence was quantified using ImageJ software. 
Since the number of cells plated were the same in each condition, we counted the number of 
fluorescent cells in the control well. (Figure IV.17.B). 
Cell exposure to 20 µg/mL of 8R-CITED2 recombinant protein led to a fluorescence 
drop to approximately 0.6, while exposure to 40 µg/mL recombinant protein caused a greater 
decrease in fluorescence. That fact can be explained by the 8R-CITED2 entrance in the cells, 
which reduced the probability of the ligation of VEC-CITED2 and VEN-CH1, causing 
consequently a decrease in the interaction of both of the residues of Venus-YFP in transfected 
cells. Taking into account the presented results, 8R-CITED2 seems to be constitutively active, 
since it competed for p300/CH1 domain. 
 
 
IV.6. 8R-CITED2  RESCUES CARDIAC DIFFERENTIATION DEFECTS CAUSED 
BY CITED2-KNOCKOUT 
To induce cardiac differentiation and further study the functionality of the 
recombinant 8R-CITED2 protein, we assessed the capacity of the 8R-CITED2 protein to 
rescue the cardiac differentiation defects caused by the depletion of Cited2 in mESC. We used 
the hanging drop method to differentiate mESC C2fl/fl[Cre] cells as described elsewhere16. At 
the beginning of differentiation (day 0), mESC are still in a pluripotent state, but during 
mESC differentiation, spontaneously contracting foci emerge and indicate that the cells have 
eventually differentiated into cardiomyocytes. These beating foci were counted from 8 to 10 
days after the initiation of differentiation (see Figure IV.18).  
 
 
Figure IV.18 - Stages of mESC development. (A) Undifferentiated mESCs cultured in 
maintenance medium in the presence of LIF represented at Day 0. (B) Hanging drop culture from 
day 2 of differentiation. (C) Embryoid body at day 5 of differentiation in suspension culture. (D) 
Embryoid body outgrowth at day 8 of differentiation in gelatine coated plate. 
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To understand if 8R-CITED2 could compensate the lack of endogenous Cited2, the 
recombinant protein was added at different differentiation days (day 0 and day 2) and at a 
concentration between 5 and 10 µg/mL to C2fl/fl[Cre], after Cited2 knockout was triggered at 
day 0 (treatment with 4HT). The process of emerging beating foci was monitored and 
compared to control cells (treated with ethanol). 
 
 
 
Analysing the graphs obtained (Figure IV.19), it was shown in both that there were no 
significant differences between the cells treated only with 4HT and 4HT supplemented with 
8R-CITED2 at day 0, which means that the recombinant protein (at least in this range of 
concentrations) was not capable to rescue the ability to differentiate into cardiomyocytes. 
These results can be explained by recent data obtained by the group (unpublished data) 
relative to the Cited2 expression. Undifferentiated aggregates of mESC were subjected to 
differentiation in hanging drops and quantitative Reverse Transcriptase-Polymerase Chain 
Reaction (qRT-PCR) were performed, being the data gently given by João Santos (Figure 
IV.20).  
 
Figure IV.19 – Comparison between C2fl/fl[Cre] treated with EtOH, 4HT and 4HT+8R-
CITED2.  (A) Percentage of colonies with beating foci and (B) average number of beating foci per 
beating EB, counted 8 to 10 days after the initiation of differentiation in cell cultures derived from 
C2fl/fl[Cre] mESC treated with 5-10 µg/mL of 8R-CITED2 at Day 0. All values are represented as 
Mean±SEM (n=3) followed by a Two-way ANOVA treatment. 
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Analyzing Cited2 RNA expression during the first few days of differentiation, we 
observed that the expression increased slightly at day 1, reached the lowest levels between 
day 2 and 3 of differentiation and increased again from day 3 to 5.  
Cited2, previously associated with pluripotency, interacts with Nanog and Oct4 
promoting self-renewal and pluripotency maintenance36,41. Since the media was supplemented 
with 8R-CITED2 at day 0 of differentiation, it would not be unexpected that the protein could 
be promoting pluripotency instead of stimulating cardiogenic pathways. After the peak at day 
1, we believe that the protein shifts towards a more cardiac interaction with another genes 
such as Isl1, therefore promoting cardiogenesis. 
In fact, preliminary results of mESC supplemented at Day 0 with an augmented 
concentration (20 µg/mL), resulted in a great reduction in the number of beating EBs and with 
40 µg/mL, that number diminished to zero. Those results leads to believe that increasing the 
amount of CITED2 protein in mESC cells contributes effectively to the maintenance of a 
pluripotency state as reported previously by Chen and co-workers.36 
Taking this information into consideration, we believed that administering the protein 
when CITED2 expression raises again (day 2) could have a more cardiogenic effect instead of 
day 0. 
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Figure IV.20 – Daily qRT-PCR analysis in aggregate differentiation of mESCs. 
Undifferentiated aggregates of mESCs were subjected to differentiation in hanging drops. Samples 
were collected since day 0 to day 5. Data show the maximum expression of Cited2 normalized by 
the reference gene GAPDH.  All values are represented as Mean±SEM (n=3). Results given by João 
Santos. 
Results and Discussion 
60 
 
Figure IV.21 – Comparison between C2fl/fl[Cre] treated with EtOH, 4HT and 4HT+8R-
CITED2.  (A) Percentage of colonies with beating foci and (B) average number of beating foci per 
beating EB, counted 8 to 10 days after the initiation of differentiation in cell cultures derived from 
C2fl/fl[Cre] mESC treated with 5-10 µg/mL of 8R-CITED2 at Day 2. All values are represented as 
Mean±SEM (n=3) followed by a Two-way ANOVA treatment. 
 
In Figure IV.21, it is possible to observe that the supplementation of 8R-CITED2 on 
Day 2 of differentiation at the same concentration in the culture medium of C2fl/fl[Cre] ESC 
treated with 4HT, resulted in the increase of the number of beating EBs along the 
differentiation days comparing them to the C2fl/fl[Cre] ESC treated with 4HT only. Regarding 
the average number beating foci in beating colonies, it is also noticeable, at Day 10, a slightly 
increase when the cells were supplemented with 8R-CITED2. 
This means that 8R-CITED2 at 5-10 µg/mL concentration proved to be capable of 
restore the number of beating EB to levels comparable to those of control cells, as we 
expected since the supplementation was made at Day 2. 
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V. CONCLUSION 
 
Cardiovascular disease is one of the main causes of death in the western world and 
novel therapeutic strategies need to be developed. One decade ago the first clinical trials 
addressed stem cell based therapies as a potential alternative therapeutic strategy for 
myocardial regeneration and repair.21 
The differentiation of pluripotent stem cells toward cardiomyocytes is a dynamic 
process involving complex signaling networks, and it is still inefficient when compared with 
other cell fates.60 Although ESC could be genetically modified to over-express cardiac-
specific transcription factors and therefore improving the efficiency of their differentiation, 
these differentiated cells are not considered safe enough to be applied in cell therapy. For that 
reason, protein transduction has been demonstrated as an alternative approach towards 
increasing the differentiation efficiency unto cardiomyocytes.  
The use of recombinant proteins associated with transcription factors can be 
transduced and in turn, stimulate over-expression of the genes that code for that protein. This 
way, they could trigger the specific pathway that is needed for differentiation toward a 
particular cell fate 25.  
In this work we developed a novel recombinant protein that combined CITED2, a 
protein involved during two different times of mESC fate (first, it maintains ESC in a 
pluripotency state and later it is involved in differentiation toward cardiomyocytes), and a 
PTD (8R), a domain enriched with arginine residues, which is capable of overcoming the 
cellular membrane barrier. 
Through different methods, it was shown that the purified 8R-CITED2, when applied 
into the studied cells, was successfully internalized, constitutively active and it presented a 
similar pattern to the endogenous protein when suppressed. While studying the role of this 
recombinant protein, it was possible to conclude that it can rescue the defects of Cited2 
knockout in mESC differentiation when applied to the media during the second day of 
differentiation, and it has some influence in the maintenance of pluripotency when media was 
supplemented at day 0.  
Through this approach, the studied protein could be used to expand mESCs in a 
controlled environment, maintaining its pluripotent state, and to better control their 
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differentiation in future applications in cell therapy and drug discovery. This method offers 
better alternatives to previously used methods of transfection that usually resulted in artificial 
systems and suboptimal levels of CITED2. However, further research is necessary to 
additionally increase the efficiency and safety of this method. 
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VI. FUTURE PROSPECTS 
 
The 8R-CITED2 revealed to be a promising molecule that fulfills the endogenous 
protein functions in mESCs. Due to limitation of time, it was impossible to explore every 
possibility of this recombinant protein.  
In this work, the culture medium was supplemented at day 0 and day 2 of 
differentiation, but other days could also be considered, like for example the administration at 
day 1 and day 3, in order to identify the optimal rescue day. Nevertheless the influence at 
pluripotency and cardiac differentiation, we cannot exclude its importance in differention later 
stages (day 7 forwards).  
As referred before, the overexpression of CITED2 sustains self-renewal and 
proliferation in mESC cultured even in the absence of LIF41, but the expression levels of this 
protein is hard to determine. Since it is possible to make a knockout of Cited2 in C2fl/fl[Cre] 
mESC, another possibility is to investigate the concentration of protein necessary to maintain 
the cells in a pluripotent state.  
The next steps could also be focused in finding possible interactions of 8R-CITED2 
with other genes involved either in pluripotency or in cardiac differentiation. For example, 
using qRT-PCR we could evaluate whereas applying the protein at day 0 would promote 
pluripotency genes while adding at day 2 would promote an increase in differentiation genes. 
In the first case, we would investigate the markers usually involved in pluripotency, such as 
Nanog, Sox2 and Oct4, in cells treated with different concentrations of the recombinant 
protein. This way, we could confirm if the entrance of the protein effectively contributes to 
the maintenance of pluripotency or even enhances it. On the other hand, our next step would 
be evaluate the expression of cardiac genes like Gata4, α-MHC, troponin, Nkx2.5 and Isl1, 
when the cells were subjected to the treatment at day 2 of cardiac differentiation.  
Then, the next logical step to the development of this work could be the application of 
the produced protein to hESC, in order to verify if the results are comparable to the obtained 
in mESC.  
If the results were similar, we could extend our studies to animal models like Cited2-
/flox; Nkx2.5Cre Mus musculus61 , that have a specific deletion of one of the alleles of Cited2. 
The phenotypical characteristics of this mouse model are: ventricular septal defects, layer of 
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ventricles and decrease in the number of capillaries to larger vessels. We could use the 
recombinant protein directly and indirectly to investigate if it could regenerate some of these 
malfunctions.  
One promising approach would be to induce heart injuries in healthy mice and study 
the role of 8R-CITED2, which ideally could stimulate the cardiomyocyte differentiation in the 
injured muscle instead of scar tissue formation.  
Taken together these approaches could contribute to evaluate the regeneration capacity 
of the heart cells, induced by the application of 8R-CITED2. 
In addition to cardiac defects, Cited2-knockout embryos die in utero with, neural tube, 
liver, lung, eye, skeletal, thymus, gonadal, hematopoietic failures, among others, as well as 
left-right patterning and neural crest cells migration defects.35,37–39 It would be interesting to 
investigate the potential of CITED2 overexpression in the survival and self-renewal of other 
tissue stem cells, activating or rejuvenating stem cells in damaged tissues or tissues 
undergoing degenerative processes.  
Besides, CITED2 might be also useful against some cancer cells, since it has been 
reported as a factor with both oncogenic and tumour suppressive properties.35,62 Since it has 
been reported that CITED2 in ESC can sustain their self-renewal, an irregular increase of 
CITED2 expression might contribute to uncontrolled self-renewal and proliferation of stem 
cells existent in tumour tissues and contribute to originate Cancer Stem Cells (CSC). 
Otherwise, in Non-Small Cell Lung Cancer (NSCLC), CITED2 was demonstrated to repress 
the expression of CSC markers in NSCLC-stem cells and enhance their sensitivity to ionizing 
radiations when in combination with butyrate treatment. So, this recombinant protein could be 
applied to these tissues to enhance the treatment to this type of cancer.35,63 
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APPENDIX B 
pGEXRC2 Plasmid Map 
(pGEX-6P-1+8R+Cited2) 
 
 
 
Sequencing Results: 
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APPENDIX C  
 
pGEXTC2 Plasmid Map 
(pGEX-6P-1+TAT+Cited2) 
 
 
 
 
 
Sequencing Results: 
 
 
